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ABSTRACT 
Patent rights are territorial.  A patent granted in the United 
States is only enforceable in the United States.  Yet increasingly so, a 
successful launch of new technology or a product requires global 
strategy, and global strategy requires global patent protection.  
Seeking patent protection in multiple countries is routine for many 
companies.  And while these multi-national teams of patent counsel 
and global administrative support are skilled at navigating different 
patentability requirements and processes, they are currently 
experiencing a new challenge: defending the priority date of their 
original patent application when seeking transnational patent 
protection.  Companies are facing this challenge because of 
differences in patent assignment laws around the world.  Patent 
assignment laws play a crucial role in patent protection, with the 
majority of patentable inventions around the world created by 
employees and assigned to employers. 
This Article demonstrates the interconnection of patent priority 
around the world by showing how the application of different rules 
regarding patent assignment law and patent priority currently lead 
to higher transaction costs and wasteful, if not abusive, litigation.  
This Article proposes two possible solutions to the global problem 
of proving patent priority: build a centralized recordation database 
modeled after the already-existing secured transactions recordation 
systems in place in almost every country worldwide, or, 
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alternatively, include a disclosure requirement in the already-
existing transnational patenting processes. 
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INTRODUCTION 
Companies are facing a new challenge: proving the priority of 
their employees’ patented inventions in post-grant patent 
proceedings.  Most often, these companies are large companies that 
have a global presence, such as Pfizer (United States), Samsung 
(South Korea), Philips (Netherlands), Novartis (Switzerland), BMW 
(Germany), and Toyota (Japan).  Yet, increasingly, this challenge is 
also faced by small to medium size companies that have a 
transnational presence, including private biotechnology and 
technology firms that commonly consider their patent portfolios as 
their most valuable asset. 
In 2016, the United States Patent and Trademark Office 
(“USPTO”) reported that eighty-five percent of the 151,000 issued 
patents were assigned to for-profit companies.1   This percentage 
reflects a slight increase over the last ten years.2  This means that the 
majority of patents in the United States rely on patent assignments 
to transfer ownership from individual inventors to companies—in 
many instances, employee to employer. 
So, while patent law scholarship is often dominated by 
discussion of the patentability requirements—namely, that an 
invention must be subject matter eligible, new, nonobvious, and 
sufficiently described,3 meeting these patentability requirements is 
 
 1 See NATIONAL SCIENCE FOUNDATION, NATIONAL SCIENCE BOARD, Chapter 8, 
Invention: United States and Comparative Global Trends (2018), 
https://www.nsf.gov/statistics/2018/nsb20181/report/sections/invention-
knowledge-transfer-and-innovation/invention-united-states-and-comparative-
global-trends [https://perma.cc/QG5J-M5FE] (breaking down the patents issued 
by the USPTO to U.S. owners in Appendix Table 8-1).  See also Ryan Abbott, I Think, 
Therefore I Invent: Creative Computers and the Future of Patent Law, 57 B.C. L. REV. 1079, 
1092 (2016) (citing this number and explaining that it is common for scientific and 
technical workers to preemptively assign their patent rights to employers as a 
condition of employment). 
 2 See Paul J. LaVanway, Jr., Patent Licensing and Discretion: Reevaluating the 
Discretionary Prong of Declaratory Judgment Jurisdiction After Medimmune, 92 MINN. 
L. REV. 1966, 1987 (2008) (reflecting similar numbers from the USPTO data).  
 3  See, e.g., Jeanne C. Fromer, Patent Disclosure, 94 IOWA L. REV. 539 (2009) 
(discussing the written description requirement); Jeanne C. Fromer, The Layers of 
Obviousness in Patent Law, 22 HARV. J.L. & TECH. 75 (2008) (discussing the 
nonobviousness requirement); Mark A. Lemley et al., Life after Bilski, 63 STAN. L. 
REV. 1315 (2011) (discussing the subject matter eligibility requirement); Richard L. 
Robbins, Subtests of “Nonobviousness”: A Nontechnical Approach to Patent Validity, 112 
U. PA. L. REV. 1169 (1964) (discussing the nonobviousness requirement); Sean B. 
Seymore, The Teaching Function of Patents, 85 NOTRE DAME L. REV. 621 (2010) 
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not enough to compete in a global market.  The patent holder must 
also have the ability to prove her ownership of the patent, most often 
by producing a written patent assignment when challenged.  This 
ownership has a direct relationship with the priority position of the 
patent holder. 4   Focusing on employee inventions, this Article 
explains how inventions are assigned differently throughout the 
world, creating a lack of transparency and unpredictable results in 
litigation.  In short, if the effective priority date—the date when the 
inventor steps into line compared to others—is changed, the patent 
will likely be invalidated. 
This is because in patent law, only one patent will be granted per 
patentable idea.  There is no independent creation defense in patent 
law, like there is in copyright law.5  The one idea, one invention rule 
is important in patent law.  Recently, Professor Lemley has 
persuasively argued that much innovation occurs near 
simultaneously, with inventors conceiving their groundbreaking 
discoveries within just weeks of one another.6  With some form of a 
first-to-file priority rule employed throughout the world, inventors 
rush to their respective country’s patent office to get the first place 
in the priority line before another inventor does the same. 
Given the global economy, it is no longer adequate protection in 
many instances to obtain patent protection solely in one’s local 
country when the patented product or method can easily be 
transported, streamed, or otherwise used and shared within seconds 
or days to far-reaching places in the world.  Obtaining international 
protection means that patent holders must prove the priority of their 
patent on a global stage.  This comes with a unique set of challenges. 
 
(discussing the written description requirement); Sean B. Seymore, Rethinking 
Novelty In Patent Law, 60 DUKE L.J. 919 (2011) (discussing the novelty requirement). 
 4  See 35 U.S.C. § 102 (2012) (outlining the “[c]onditions for patentability; 
novelty and loss of right to patent” in the United States); Robert P. Merges, Priority 
and Novelty Under the AIA, 27 BERKELEY TECH. L.J. 1023, 1024 (2012) (identifying the 
filing of a patent application as the critical date and the relevance of worldwide 
prior art). 
 5 See Fred Fisher, Inc. v. Dillingham, 298 F. 145, 147 (S.D.N.Y. 1924) (citing 
Judge Hand’s famous explanation: “One may infringe a patent by the innocent 
reproduction of the machine patented, but the law imposes no prohibition upon 
those who, without copyright, independently arrive at the precise combination of 
words or notes which have been copyrighted.”). 
 6 See Mark A. Lemley, The Myth of the Sole Inventor, 110 MICH. L. REV. 709, 711 
(2012) (providing many examples of the social phenomenon of simultaneous 
invention). 
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A recent opinion from the District Court in The Hague is 
exemplary.7  In this opinion, two U.S. patent applications were filed 
naming two employee-inventors as the applicants.  These employee-
inventors worked for a U.S.-based multinational biotechnology 
company.  At the time, U.S. patent law required the inventors to be 
named as the patent applicants, as opposed to the company that they 
worked for named as the inventor.  Within the applicable 12-month 
period permitted by international law,8 the biotech company filed a 
single foreign application through the Patent Cooperation Treaty 
(“PCT”) based on the U.S. patents (and claiming their priority date), 
naming the biotechnology company as the applicant.  For a PCT 
application, a company, not an individual inventor, is the 
appropriate applicant, although the inventors must still be 
identified in the PCT application. 
The biotech company was granted a European patent stemming 
from the PCT application, which vested in the biotech company and 
claimed the priority date of the earlier filed U.S. patent applications.  
In a post-grant European opposition challenging the validity of the 
European patent, it was argued that the priority claim was 
inappropriate due to, in essence, a break in the chain of title.  Simply, 
the applicants were different from the U.S. patent applications to the 
PCT applications.  The problem?  The biotech company must now 
prove that it had a proper assignment of the right to priority from the 
two inventors to their employer, the biotech company. 
In the United States, the right of priority is not independent from 
the right to the patent itself.  Accordingly, practitioners do not need 
a separate, formal assignment of the right of priority.  Elsewhere, 
and in much of Europe, this right is separate, and as such, must be 
explicitly assigned separate from the patent.  Ultimately, despite 
each patent application, those in the United States and the PCT 
application, effectively and appropriately filed when viewed apart 
from one another, the biotech company could not prove that the 
right to priority had been properly assigned to it by the time the PCT 
application was filed.  Consequently, the biotech company’s 
 
 7 See Celltrion Inc. v. Biogen Inc. et al., Case No. C/09/519083/ HA ZA 16-
1117, Decision, District Court of the Hague (Sept. 27, 2017) [hereinafter Celltrion 
Inc. v. Biogen Inc. et al.], https://uitspraken.rechtspraak.nl/inziendocument?id=
ECLI:NL:RBDHA:2017:11301 [https://perma.cc/66RJ-R95X]. 
 8 See Paris Convention for the Protection of Industrial Property art. 4, Mar. 20, 
1883, 21 U.S.T. 1583, 828 U.N.T.S. 305 (According to Article 4 of the Paris 
Convention for the Protection of Industrial Property (Paris Convention), there is a 
12-month right of priority as of the date of these U.S. patent applications filing).  
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European patent was invalidated in the European post-grant 
proceeding.  Yet, in a different forum, on appeal, the District Court 
of The Hague, the exact opposite conclusion was found: the 
biotechnology company was permitted to retain the priority date for 
the European Patent. 
This example is not unique.  Defending the priority of a patent 
priority should, in theory, come down to a seemingly simple chain-
of-title analysis.  Yet, because the rules of patent assignment laws 
vary substantially from country to country, this simple analysis is 
quite complicated.  Moreover, the vast majority of patentable ideas 
and inventions are created by employee-inventors and assigned to 
employers, meaning that these differences in patent assignment 
laws creates uncertainty, as well as wasteful, inefficient litigation in 
post-grant proceedings around the world.  Finally, differences in 
patent assignment laws result in lost opportunities for cross-border 
collaboration. 
This Article argues that a centralized recordation database be 
created and housed by the World Intellectual Property Organization 
(“WIPO”), one that will track the chain of title of international 
patents.  Alternatively, WIPO, and/or the proposed European 
unitary patent system should require a few extra additional 
disclosures during the PCT and/or unitary patent filing process to 
achieve transparency and predictability. 
Part 1 discusses patent priority, including identifying the 
significance of priority and novelty, and the recent rise in priority 
challenges throughout the world.  Part 2 identifies the relevant laws 
affecting patent priority for those claiming patent priority from U.S. 
applications.  Part 3 then identifies the relevant laws affecting patent 
priority for those claiming patent priority from countries in Europe, 
notably the Netherlands and Germany.  These two countries have 
routinely seen their patent holders lose patent priority dates, and 
both stand at a stark contrast to a common law system like that of 
the United States.  Part 4 does the same identification for patent 
priority stemming from countries in East Asia, including Japan, the 
Republic of Korea, and China.  Finally, Part 5 provides suggestions 
on how to increase the predictability of priority challenges, thereby 
decreasing inefficient and burdensome post-grant litigation. 
Published by Penn Law: Legal Scholarship Repository,
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1. PATENT PRIORITY & THE RISE IN PRIORITY CHALLENGES IN THE 
IP5 OFFICES 
This Article will focus on the patent laws within the jurisdictions 
of five particular intellectual property offices.  The five offices are 
the European Patent Office (“EPO”), the Japan Patent Office (“JPO”), 
the Korean Intellectual Property Office (“KIPO”), the National 
Intellectual Property Administration of the People’s Republic of 
China (“CNIPA”), and the United States Patent and Trademark 
Office (“USPTO”). 
These five intellectual property offices comprise the “IP5.”  The 
IP5 is a cooperation between the five largest intellectual property 
offices in the world.  Together, these five offices “handle about 80 
percent of the world’s patent applications, and 95 percent of all work 
carried out under the Patent Cooperation Treaty (“PCT”).”9 
Recognizing the opportunity for natural synergies with this high 
volume of patenting, during the first ten years of the IP5 Offices co-
operation, the IP5 Offices directed their efforts at “improv[ing] the 
efficiency of the examination process for patents worldwide.” 10  
Over the course of the past decade, the IP5 Offices have 
commissioned many studies to assess the evolving global need of its 
users.  As a result, a new vision of the IP5 Offices was published in 
2017: “Patent harmonization of practices and procedures, enhanced 
work-sharing, high-quality and timely search and examination 
results, and seamless access to patent information to promote an 
efficient, cost-effective and user-friendly international patent 
landscape.”11 
The IP5 is so exciting precisely because of the recognition of the 
evolving needs of innovators throughout the world.  Global 
collaboration and coordination are made more possible when the 
five largest players act together in their combined users’ interests. 
One of the first projects the IP5 Offices undertook was to build a 
catalogue for its users displaying the areas in which patent practices 
 
 9  About IP5 co-operation, FIVE IP OFFICES, https://www.fiveipoffices.org/
about.html [https://perma.cc/2J26-QBQH] (last visited Feb. 22, 2019). 
 10 Id.  See also Areas of Activity, FIVE IP OFFICES, https://www.fiveipoffices.org/
activities.html [https://perma.cc/5L66-KAUT] (last visited Feb. 22, 2019) 
(Moreover, “[t]he vision of the IP5 Offices is global co-operation, which has been 
defined as ‘the elimination of unnecessary duplication of work among the IP5 
Offices, the enhancement of patent examination efficiency and quality of guarantee 
of the stability of the patent right.’”). 
 11 About IP5 co-operation, supra note 9. 
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differed between the five offices.12  Two areas in this catalogue that 
received special attention: priority and novelty.13  
The determination of which inventor receives the sole patent is 
governed by the so-called “priority rule.”  The priority rule tackles 
the “compared to whom” question. 14   Yet the determination of 
whether the inventor gets to claim its invention is the first of its kind 
is governed by the novelty patentability requirement.  The novelty 
patentability requirement tackles the “compared to what” 
question.15 
Starting with the priority rule, there are two general options: the 
“first-to-invent” rule and the “first-to-file” rule.  Most basically, 
should the patent claimant who was first in time to invent receive the 
patent or, instead, should the patent claimant who was the first to 
file a patent application receive the patent?  The first-to-invent 
priority rule was a longstanding hallmark of the U.S. patent 
system.16  Yet when President Obama signed the America Invents 
Act (“AIA”) into law, U.S. patent law moved towards a first-to-file 
rule.  Most simply, if there is a priority dispute regarding a patent 
filed on or after March 16, 2013, in the United States, the dispute is 
most often settled by determining which inventor was the first to file 
its respective patent application.17 
When the United States adopted the first-to-file priority rule, 
there was hope that there would be meaningful international patent 
harmonization.  Yet the United States “did not in fact adopt the 
 
 12  See Catalogue of Remaining Differences, FIVE IP OFFICES (2012), 
https://www.fiveipoffices.org/wcm/connect/fiveipoffices/f52e30ce-ac79-4a23-
bfca-b370df61683d/catalogue_of_differing_practices_2012_update.pdf?
MOD=AJPERES&CVID= [https://perma.cc/JAE3-YTMR] (last visited Feb. 22, 
2019) (listing the categories of differing practice between IP5 offices). 
 13  See IP5 Statistics Report, FIVE IP OFFICES (2014), 
http://www.fiveipoffices.org/statisticsreports/2014edition/ip5sr2014.pdf 
[https://perma.cc/6XY7-35E2] (last visited Feb. 22, 2019) (explaining that 
“Priority” is a term of art, and yet it is not defined consistently throughout the 
worldwide patent laws). 
 14 See Merges, supra note 4, at 1028 (“Strictly speaking, priority is a question of 
who, as between two rival inventors, will obtain a patent for an identical invention . . . . 
Novelty is a question of whether, as between an inventor and a piece of prior art, the 
inventor acts before or after the prior art enters the field.”). 
 15 See id. (“if an inventor can show that he or she did whatever is required 
before a reference enters the prior art, the inventor gets the patent.”). 
 16  See David S. Abrams & R. Polk Wagner, Poisoning the Next Apple? The 
America Invents Act and Individual Inventors, 65 STAN. L. REV. 517, 520 (2013) (defining 
the first-to-invent rule as granting patent priority to “the party that had the 
inventive idea first”). 
 17 Id. at 519. 
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[first-to-file priority] rule in the way that the international 
community understands the first-to-file rule.”18  The international 
community, including the other IP5 Offices, follows what is 
commonly termed the “absolute” novelty rule.  An absolute novelty 
rule is just as it sounds: it follows a “pure first to file system,” 
meaning “that if there is a use, sale or publication of information 
relating to the invention prior to the filing of a patent application[,] 
no patent can be obtained.”19 
Instead of the absolute novelty rule, the rule the United States 
adopted permits an inventor to prove priority in two ways other 
than the earliest filing date: “(1) where the first filer learned of or 
outright stole the invention from another person; and (2) where the 
second filer made a public disclosure of the invention before the first 
filer filed a patent application.”20  Accordingly, the United States 
adopted a first-proven-inventor-to-file rule, where an inventor 
proves her priority either by filing a patent application to reserve 
her place in line at the USPTO, or by making a widely available 
disclosure.21 
This means that unlike the first-to-invent priority rule that places 
the highest value on the first conception of the new invention, the 
first-to-file priority rule in the United States most values the first 
public disclosure of the new invention.  This disclosure may be 
either making a widely available disclosure, such as through a 
printed publication, or by simply filing a patent application.  In the 
United States, these events start the twenty-year clock that runs 
before the invention goes into the public domain.  
While the United States and other countries mostly agree now 
on the priority rule to use when determining the priority date of any 
given invention, the international community does not agree on the 
level of novelty.22  A novelty dispute concerns one inventor and her 
 
 18 Karen E. Sandrik, A Uniform Grace Period: Promoting International Research 
and Development Collaboration, 91 TUL. L. REV. 99, 104 (2016). 
 19  Gene Quinn, Patentability: The Novelty Requirement of 35 U.S.C. 102, 
IPWATCHDOG (June 10, 2017), http://www.ipwatchdog.com/2017/06/10/patent
ability-novelty-requirement-102/id=84321/ [https://perma.cc/CXB3-82N5]. 
 20 Merges, supra note 4, at 1028. 
 21 See, e.g., Merges, supra note 4, at 1046 (“While the AIA moves the United 
States to a first-inventor-to-file system, it does not go all the way to complete 
international harmonization.”). 
 22 For an example of the varying language used regarding this topic, see Gene 
Quinn, Harmonization and the Quest for an Elusive International Grace Period, 
IPWATCHDOG (Feb. 10, 2015), https://www.ipwatchdog.com/2015/02/10/
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claimed invention compared to the already existing references 
composing the relevant prior art.23  What constitutes prior art is a 
difficult question to answer, especially when comparing the answer 
to other answers to this question around the world.  In the United 
States, the basic novelty rule requires that an inventor’s claimed 
invention is new compared to all previously granted patents, 
published patent applications, and printed applications across the 
world. 24   The claimed invention must also be new compared to 
inventions anywhere in the world that are already in the public’s 
use, already on sale, or otherwise available to the public.25 
In regards to the specific timing of the comparison between the 
claimed invention and the prior art, the Patent Act defines the 
“effective date” as the filing date of a patent application.26  While it 
is no longer possible to antedate, or back-date, a patent application 
under current patent law, “the effective filing date of a claimed 
invention is [still] determined on a claim-by-claim basis and not an 
application-by-application basis.” 27   This is because claims may 
have different geneses, such as the actual filing date of the patent-
at-issue in the United States versus a right to priority of a patent 
application filed in a foreign country.28 
While the novelty rule is not central to this Article, it is important 
to realize the impact the priority date has on the novelty of an 
invention.  If, due to a successful priority challenge, the effective 
date is pushed back one year or even just a few months, there will 
 
harmonization-and-the-quest-for-an-elusive-international-grace-period/
id=54599/ [https://perma.cc/DA2Y-YTZD] (discussing the “grace period”). 
 23 See Merges, supra note 4, at 1030 (explaining the general rule of novelty and 
its exceptions “to the general rule that, to be valid, an application has to be filed 
before a prior art event”). 
 24 (a) NOVELTY; PRIOR ART.—A person shall be entitled to a patent 
unless—(1) the claimed invention was patented, described in a printed 
publication, or in public use, on sale, or otherwise available to the public 
before the effective filing date of the claimed invention; or (2) the claimed 
invention was described in a patent issued [to another] or in [another’s] 
application for patent [that is] published [and that] . . . was effectively filed 
before the effective filing date of the claimed invention.  
See 35 U.S.C. § 102(a) (2012). 
 25 35 U.S.C. § 102(a) (2012). 
 26 35 U.S.C. § 101(b) (2018). 
 27  Manual of Patent Examining Procedure, U.S. Patent and Trade Office, 
2152.01 (last revised Jan. 2018) [hereinafter MPEP], https://mpep.uspto.gov/
RDMS/MPEP/e8r9#/current/ch2100_d20033_1afb3_e6.html 
[https://perma.cc/EFA5-XGRW]. 
 28 See 35 U.S.C. § 119 (2018). 
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almost certainly be new prior art references that will serve to destroy 
the once-thought novelty of the at-issue invention.  Overall, if a 
patent holder cannot defend the priority date of the original patent 
application, the patent holder will either lose out to a competing 
patent application with the superior claim to the invention, or the 
patent holder may very well lose her ability to claim her invention 
is new and/or nonobvious.   
The following two subparts will show the rise in priority 
challenges of post-grant patents in Europe, and then briefly explain 
the basics of the relevant post-grant patent opposition and 
invalidation systems of the IP5 Offices. 
1.1. The Sudden Rise in Priority Challenges 
In the past 15 years, there has been an explosion in post-grant 
patent priority challenges.  Although the rise in priority challenges 
is most visible in Europe, the potential for these type of priority 
challenges also exists in the United States, Japan, and the Republic 
of Korea (“Korea”), among other countries outside of the IP5 
Offices.29 
Extrapolating from recent case law, it appears that patent 
challengers may have learned about challenging chain-of-title on the 
grounds that there should be a separate and express assignment of 
the right of priority from a 2006 European Opposition opinion.30  In 
that opinion, the board held that the patent holder, GE Plastics Japan 
K.K., had not carried its burden to prove that its priority date, 
claiming priority from a Japanese patent application, was valid.31  
The problem is that the applicant for the Japanese patent application 
was GE Plastics Japan K.K., whereas the applicant for the European 
Patent was General Electric Company. 32   Subsequently, and 
presumably not until the potential chain of title problem was noticed 
 
 29 See infra Parts 2-4. 
 30 GE Plastics Japan K.K. v. Koninklijke DSM N.V., No. T 0062/05, Decision, 
Bd. of App. of the Eur. Patent Office (Nov. 14, 2006). 
 31 See id. at 24 (“The Board, after deliberation, informed the Parties, that the 
priority claim could not be considered as valid . . . .”). 
 32 See id. at 10 (“There was a lack of identity of the proprietor of the priority 
right based on JP 2498697 and the proprietor of the contested patent . . . ”).  See also 
id. at 28 (identifying the issue that “priority is claimed . . . by different persons as 
can be seen from the European patent application (i.e. General Electric Company) 
and the priority document (i.e. Nihon GE Plastics K.K.)”). 
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nearly seven years after the filing date of the European Patent 
application, General Electric transferred the at-issue right of 
priority, as well as the European Patent, to GE Plastics Japan K.K.  
This assignment was not within the twelve-month priority window, 
and the assignment could not retroactively overcome the chain-of-
title issue presented by the two different applicants. 
The patent holder, GE Plastics Japan K.K., did present evidence 
that GE Plastics Japan K.K. had assigned the patent application to 
General Electric Company, but it could not present evidence that it 
had expressly assigned the right of priority.  It attempted to make 
the argument that it, in essence, would be “illogical for GE Plastics 
Japan to assign the application to [the parent company,] General 
Electric Company[,] without assigning the corresponding priority 
rights,”33 yet the board was unconvinced. 
Instead, the board seemed to focus on the idea that “[p]riority 
rights are assignable independently of the corresponding patent 
application . . . .” 34  And although the board explained that “the 
European Patent Convention (“EPC”) does not contain any 
regulations concerning the formal requirements that an assignment 
of priority rights for the filing of an European patent application 
should fulfill in order to be considered valid,” the board also found 
that because the priority date on a patent has a “crucial effect,” the 
transfer of priority rights should, “in the Board’s view, be proven in 
a formal way.”35  The board found support in a different part of the 
EPC, Article 72, which requires that the assignment of an European 
Patent application be in writing and “signed by or on behalf of the 
Parties to the transaction.”36 
Overall, GE Plastics K.K. could not meet this formal requirement 
of a written and independent assignment.  As a result, it lost its 
priority date. 37   As mentioned above, the consequence of losing 
one’s priority date is twofold: one, there is the potential that another 
inventor is now ahead in the so-called priority line for the one 
patent; and two, the invention is no longer new, now failing to meet 
the novelty requirement.  Either way, the effect is devastating to the 
patent holder: the patent, in effect, loses its monetary value, if it is 
affirmed at all (as opposed to invalidated altogether). 
 
 33 Id. at 23. 
 34 Id. at 29. 
 35 Id. 
 36 Id. at 30. 
 37 Id. at 32. 
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Showing the downstream impact of this 2006 opinion is a more 
recent opinion.  This 2015 opinion demonstrates some of the 
development in the approximately ten years since the 
groundbreaking 2006 opinion. 
In the 2015 opinion, Teva Pharmaceutical Industries Ltd. had a 
post-grant patent challenged by multiple competitors in a European 
Opposition.38  Teva’s patent, European Patent No ‘489, was issued 
from a patent application that was filed through what is sometimes 
termed an international application or a PCT application, 39  on 
August 23, 2005.  This international application claimed priority 
from two U.S. provisional applications, with the earliest priority 
date of August 23, 2004.40 
In the European Opposition, the patent challengers argued that 
Article 87 of the European Patent Convention “require[s] a separate 
and express assignment of the right of priority executed by the 
applicants of the provisional US applications,” the ones upon which 
priority for EP ‘489 is based.41  While the statute does not explicitly 
state an assignment of the right of priority must be done in a 
separate and express assignment, Article 87 does provide that 
applicants, or “his successors in title, shall, enjoy, for the purpose of 
filing a European patent application in respect of the same 
invention, a right of priority during a period of twelve months from 
the date of filing of the first application.42 
 
 38 Teva Pharmaceutical Indus. Ltd v. Hexal AG, No. T 0205/14, Decision, Bd. 
of App. of the Eur. Patent Office (June 18, 2015).  Ultimately, Teva’s patent was 
invalidated due to lack of inventive step, the United States equivalent of non-
obviousness.  See also id. at 50-66.  
 39 The Patent Cooperation Treaty (“PCT”) is a World Intellectual Property 
Organization (“WIPO”) system that: 
[A]ssists applicants assists applicants in seeking patent protection 
internationally for their inventions, helps patent Offices with their patent 
granting decisions, and facilitates public access to a wealth of technical 
information relating to those inventions. By filing one international patent 
application under the PCT, applicants can simultaneously seek protection for 
an invention in a very large number of countries.”  
PCT—The International Patent System, WORLD INTELLECTUAL PROPERTY 
ORGANIZATION (WIPO), http://www.wipo.int/pct/en/ [https://perma.cc/DVL4-
WL4Q] (last visited Feb. 23, 2019). 
 40 See Teva, supra note 38, at 1. 
 41 See Teva, supra note 38, at 6. 
 42 European Patent Convention art. 87(1) Convention art., Oct. 5, 1973, 1065 
U.N.T.S 199 [hereinafter EPC], [https://perma.cc/K7ER-74V3].  Article 87 
expressly refers to the Paris Convention for the Protection of Industrial Property 
(Paris Convention), which has very similar language to Article 87.  Article 4 of the 
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The board started its discussion with Article 87(1), the same 
article at issue in the 2006 decision, stating that: 
[T]he right to claim priority for a European patent 
application from the filing date of . . . [a] previous 
application . . . originates in the applicant of said first 
application.  Therefore, in principle, the applicant has to be 
the same for the first application and for the subsequent 
applicant for which the right of priority is invoked.43  
The board then noted that a successor in title is also able under 
the statute to claim the right of priority.44  As to the right of priority 
itself, the board explained that the right of priority is “an 
independent right up and until it is invoked for one or more later 
applications to which it becomes an accessory.”45  Yet even so, this 
board disagreed that the independence, the severability of the right 
to priority, must be likewise assigned in a “separate and express 
assignment.”46  This stands in sharp contrast to the holding from the 
2006 European Opposition opinion.  Here, the board decided that 
because Article 87(1) was silent as to formalities, that this silence was 
not an invitation to read any such formalities into it.  As such, “the 
present board cannot follow [the 2006 board’s] reasoning.”47 
When determining which law to apply in regard to the right of 
priority assignment to a successor in title, this board stated that 
Article 72 is distinct from Article 87.  Article 72 represents a 
collective law that specifically overrules national law, “which, in 
general, governs legal acts related to property interests in such 
applications[.]”48  After further discussion, this board decided that 
the silence of Article 87 should be construed as carrying with it no 
 
Paris Convention provides for an international right of priority, lasting 12 months 
as of the date of filing of a patent application for filing in other countries.  Just as 
with EPC Article 87, this right is conferred to “any person who has duly filed an 
application for patent . . . in one of the countries of the Union, or his successor in 
title.”  Paris Convention for the Protection of Industrial Property, as last revised at 
the Stockholm Revision Conference, Mar. 20, 1883. 21 U.S.T. 1583, 828 U.N.T.S. 305, 
supra note 8. 
 43 Teva, supra note 38, at 24. 
 44 Teva, supra note 38, at 24 (“the right of priority may also be invoked by the 
‘successor in title’ of the person who has filed the first application . . . it is 
recognised  that the right of priority . . . may be transferred from the original 
applicant to a third person.”). 
 45 Teva, supra note 38, at 24 
 46 Teva, supra note 38, at 25. 
 47 Teva, supra note 38, at 26-27. 
 48 Teva, supra note 38, at 27-28.  
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formal requirements, and that because the EPC provisions do not 
directly answer questions of this type of assignment, the validity of 
transfer of a priority right “is a matter of national law.”49  
As a result, parties before the Boards of Appeals of the EPO, and 
first the Opposition Division, must navigate not only the intricacies 
of patentability requirements, but also which law, and what formal 
requirements, are going to be imposed upon any successor in title.  
Assigning patents from the original inventor(s) to another, a 
successor in title, is an everyday practice for companies such as 
General Electric and Teva Pharmaceuticals.  On the one hand, 
requiring those companies to understand and navigate specialized 
rules is fair.  On the other hand, when all companies, both large and 
small, have a shifting target as to what law applies, with some not 
permitted to obtain written patent assignments at early stages due 
to national patent law, it becomes an impossible task of navigation. 
1.2. Challenging Post-Grant Patents in the IP5 Offices 
Since the 1970s, the EPO has provided a way for petitioners to 
challenge issued patents in post-grant opposition proceedings.50  As 
such, the EPO is the experienced leader of the other IP5 Offices.  That 
said, there is change coming to Europe with the likelihood that a 
Unified Patent Court (“UPC”) will be introduced sometime soon, 
change that may shake up this previously consistent stability that is 
so attractive to patent applicants and patent challengers. 51   The 
 
 49 Teva, supra note 38, at 30 (citing references omitted). 
 50  See, e.g., Olga Partington & Paul Calvo, On the Attack, EUR. 
BIOPHARMACEUTICAL REV. 66, 68 (2015) (describing the European post-grant 
opposition proceedings as more favorable to challengers than American 
proceedings because of the few substantive requirements placed on challengers 
during EPO proceedings); Filip De Corte, Anthony C. Tridico, Tom Irving, Stacy D. 
Lewis & Christina N. Gervasi, AIA Post-Grant Review and European Oppositions: Will 
They Work in Tandem, or Rather Pass Like Ships in the Night?, 14 N.C. J.L. & TECH 93, 
98-99 (2012) [hereinafter AIA Post-Grant Review] (“Oppositions allow third parties 
(other than the applicant and the EPO) to bring forward facts and arguments that 
are prejudicial to the patentability of the invention that is claimed in the opposed 
patent.”). 
 51 For the most recent status of the Unified Patent Court (UPC), see Agreement 
on a Unified Patent Court, 2013 O.J. (C 175) 1.  Most notably, Germany has yet to 
ratify the agreement that would establish the UPC and a unitary patent.  Id.  The 
EPO is currently stating on its website that “[t]he start of the new system is currently 
expected for the first half of 2019.”  When Will the Unitary Patent System Start? 
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United States, with the AIA, only recently adopted a robust post-
grant opposition system, one that is similar to the EPO post-grant 
opposition.  In 2015, just a few years after the AIA, Japan 
reintroduced its previously terminated post-grant opposition 
system.  Similarly, Korea just reintroduced its previously terminated 
system in 2017.  And although China does not currently have a post-
grant opposition system, the CNIPA, like the other IP5 Offices, does 
have the traditional litigation-based invalidation option to challenge 
patents after they are granted.   
This subpart will briefly give the highlights of each system to 
impart a basic understanding of how priority dates of previously 
filed patents are most often being challenged.  If the reader is already 
familiar with post-grant oppositions in the IP5 Offices, please 
proceed to Part 2. 
Starting with the post-grant opposition system in Europe, 
European oppositions must be filed within nine months of patent 
issuance.52  Assuming a petitioner pays the appropriate fees and 
follows other basic filing procedures, anyone can file a petition 
against as many patent claims as the petitioner can support. 53  
Perhaps to increase the motivation to challenge potentially dubious 
or weak patents, the petitioner does not have to reveal the real party 
behind the petition.54  This is commonly called the “straw man” 
opposition,55 which thereby permits potential competitors to shield 
 
EUROPEAN PATENT OFFICE, https://www.epo.org/law-practice/unitary/unitary-
patent/start.html [https://perma.cc/7AQX-8K5N] (last visited Feb. 23, 2019). 
 52 Chapter 5: The European patent grant procedure. EUROPEAN PATENT GUIDE 59 
(19th ed. 2019), http://documents.epo.org/projects/babylon/eponet.nsf/
0/8266ED0366190630C12575E10051F40E/$File/how_to_get_a_european_patent_
2019_en.pdf [https://perma.cc/ZAZ4-8JWS]. 
 53 EPC, supra note 42, at art. 99(1):  
Within nine months of the publication of the mention of the grant of the 
European patent in the European Patent Bulletin, any person may give notice 
to the European Patent Office of opposition to that patent, in accordance with 
the Implementing Regulations. Notice of opposition shall not be deemed to 
have been filed until the opposition fee has been paid. 
 54 See Michael J. Flibbert, Leythem A. Wall, & Maureen D. Queler, Coordinating 
European and U.S. Post-Grant Patent Opposition, FINNEGAN (Nov. 4, 2014), 
https://finnegan.com/en/insights/coordinating-european-and-u-s-post-grant-
patent-opposition.html [https://perma.cc/FG37-TSXA] (explaining how 
petitioners may use the “straw man” provision” to file under the name of a different 
party and conceal their identities). 
 55 STERNE, KESSLER, GOLDSTEIN & FOX, P.L.L.C., EUROPEAN PATENT OFFICE (eds. 
Jason D. Eisenburg & Robert Greene Sterne) 1 PATENT OFFICE LITIGATION § 23:5 
Westlaw (database updated Jan. 2017) [hereinafter PATENT OFFICE LITIGATION] (“If 
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their identity.  This is particularly useful if the petitioner is a licensee 
of the patent or a direct competitor of the patent holder. 
A filed opposition may challenge the subject matter of the 
European patent, the written description of the European patent, or 
that the subject matter of the European patent is broader than the 
application itself, whereby the patent “extends beyond the content 
of the application as filed[.]”56  This means that if the priority date of 
the patent is incorrect due to a break in the chain-of-title, the change 
of a priority date will almost always likewise impact the written 
description and enablement of the patent.  Thus, grounds for 
opposition necessarily also include a challenge that the priority date 
of the patent is incorrect, as demonstrated by the EPO decisions 
above.  For a discussion of this very point, the following is 
illustrative: 
[I]f the appellant’s right to priority is denied, that could only 
be for subject matter disclosed in the earlier UK application.  
That application disclosed only the embodiments using a 
self-closing slit valve in a dome-shaped region whereas the 
subsequent UK application contains both the dome-shaped 
and the flat end embodiment.  Thus[,] the only subject matter 
which could lose priority is the dome-shaped region subject 
matter, because Article 87(4) EPC cannot apply to the 
alternative flat end subject matter[,] which was not in the 
earlier application[,] but only in the subsequent UK 
application.  Hence, for the flat end embodiment the priority 
date of 7 April 1992 must be valid.57 
In terms of filing fees, the European opposition process is 
affordable, with an official fee around $1,000 U.S. that is 
independent of how many claims are challenged or grounds for 
such challenges are asserted. 58   The petitioner may challenge a 
European patent on a number of grounds, including: 
 
the opponent does not wish to identify themselves (possibly because of a 
commercial interest) it is permitted for another person to file the opposition on their 
behalf—this is known as a ‘straw man’ opposition.”). 
 56 EPC, supra note 42, at art. 100. 
 57  Decision of the Technical Board of Appeal 3.2.2, T 1056/01, BOARDS OF 
APPEAL OF THE EUROPEAN PATENT OFFICE, 5 (June 4, 2003), 
https://www.epo.org/law-practice/case-law-appeals/recent/t011056eu1.html 
[https://perma.cc/9QV4-W9HM]. 
 58  See Schedule of Fees, EUROPEAN PATENT OFFICE, https://my.epoline.org/
portal/classic/epoline.Scheduleoffees [https://perma.cc/N6FN-FUEW] (last 
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[1] that the subject-matter of the patent is not patentable 
within the terms of Articles 52-57 EPC, [2] that the invention 
is not disclosed clearly and completely enough for a person 
skilled in the art to carry it out, [and 3] that the patent’s 
subject-matter extends beyond the content of the application 
as filed.59 
Upon this reexamination of the European patent, the opposition 
may be rejected (and the patent validity is, in essence, affirmed), the 
patent is amended with a new patent specification, or the patent is 
revoked.60 
The timeline of the post-grant process from start to finish is 
generally within an eighteen to thirty-month turnaround, with 
many oral decisions granted in a fifteen to twenty-four-month 
timeline.61  As a result, European oppositions are a cost-effective and 
time-efficient mechanism for centrally challenging a European 
patent. 
Conversations in the United States leading up to the AIA 
included discussion of international harmonization, including the 
adoption of a first-to-file priority rule and also the introduction of a 
post-grant opposition proceeding similar to that of the EPO 
described above. 62   Arguably trying to achieve this stated policy 
 
visited Mar. 5, 2018) (listing the possible fees associated with the EPO application 
process). 
 59  Oppositions, EUROPEAN PATENT OFFICE, https://www.epo.org/applying/
european/oppositions.html [https://perma.cc/8Y72-X6ML] (last visited Feb. 20, 
2019). 
 60 Id. 
 61 See Flibbert, Wall, & Queler, supra note 54. 
 62 See, e.g., 157 CONG. REC. 4369, 4428 (statement of Rep. Manzullo) (“This bill 
would finalize the shift towards a European-style patent system through changing 
from a ‘first-to-invent’ to ‘first-to-file’ system; establishing a new set of ‘prior use’ 
rights; and adopting a third European style ‘post-grant’ challenge.”).  Prior to the 
implementation of the AIA, post-grant ex parte reexamination and inter partes 
reexamination proceedings were available.  See 35 U.S.C. § 305 (2012) (describing 
the process of reexamination proceedings).  This pre-AIA system fell short of an 
ideal reexamination process.  Criticism of pre-AIA post-grant proceedings included 
charges of insufficient third-party involvement, unfair bias favoring the patent 
holder, and lack of international harmonization of post-grant proceedings.  See 
Jeffrey P. Kushan, The Fruits of the Convoluted Road to Patent Reform: The New 
Invalidity Proceedings of the Patent and Trademark Office, 30 YALE L. & POL’Y REV. 385, 
391 (2012) (regarding criticism of unfair bias favoring the patent holder and the lack 
of international harmonization of post-grant proceedings); Christopher L. Logan, 
Patent Reform 2005: HR 2795 and the Road to Post-Grant Oppositions, 74 UKMC L. REV. 
975, 988-89 (2006) (explaining failures in the pre-AIA system, including insufficient 
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aim, the AIA introduced significant changes to the U.S. post-grant 
opposition system.  This included the introduction of post-grant 
review (“PGR”), inter partes review (“IPR”), and covered business 
method review (“CBM”).  After issuance of a patent, PGR is initially 
the only adversarial proceeding available to challenge the validity 
of the patent within the USPTO.  As in Europe, and the other 
countries housing the four other IP5 patent offices, there is always 
the traditional option of litigation (through district court litigation 
in the United States) to challenge an issued patent. 
Available grounds for challenging the patent through PGR 
include the following patentability requirements: subject-matter 
eligibility, novelty, nonobviousness, and the written description.63  
Not just anyone can file a PGR petition: those who have already or 
are currently in the process of challenging the validity of the same 
patent in a U.S. patent infringement lawsuit may not use the PGR 
process offered in the United States.64 
Notably, unlike that of the European opposition, the U.S. PGR 
requires that the real party behind the petition be revealed to the 
public.65  Yet like a European opposition, the PGR petition must be 
filed within nine months of the patent grant.66  A PGR petition is 
submitted to the newly created PTAB, which is staffed by 
administrative patent judges, many of whom are experienced patent 
prosecutors and, or, patent litigators.67  Although PGRs are similar 
to European opposition proceedings, they are not as popular. 68  
 
third-party involvement and the estoppel provision).  Although Congress initially 
looked to the example of European opposition proceedings, much changed during 
the course of legislation.  Today, there are still arguments to be made that the United 
States’ system is disappointingly distinct from that of the European Patent Office.  
See Karen E. Sandrik, The Post-Grant Life: Coordinating & Strategizing Challenges of 
Issued Patents in Multiple Continents, 17 CHI. -KENT. J. INTELL. PROP. 449, 450-51 (2018) 
(arguing the lack of international harmonization creates opportunities for 
inefficient strategic behaviors). 
 63 See 35 U.S.C. § 321(b) (2012). 
 64 See id. at § 325(a)(1). 
 65 Id. at § 322(b). 
 66 Id. at § 321(c). 
 67 See Michael Wagner, An Introduction to Administrative Patent Judges at the 




 68  Jeffrey A. Miller, Katie J.L. Scott, & Bonnie Phan, Post-Grant Review: A 
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Presumably, one reason is the expense associated with a PGR.  
Unlike the low filing fee of the European opposition proceedings, 
the minimum filing fee of a PGR is $38,000 U.S., which covers 
patents with up to twenty claims.69  There are additional fees for 
every claim over twenty that is challenged.70 
After the nine-month PGR period has expired, or after the 
termination of any PGR that has been instituted as to the at-issue 
patent, an IPR or CBM petition may be filed.  Unlike in PGR or in a 
European opposition, an IPR petition may only challenge an issued 
patent on limited grounds, including failure to satisfy the novelty or 
nonobviousness requirements, which must be argued only on the 
basis of prior patents or printed publications.71  Similar to PGR, IPR 
challenges are available to anyone with a couple of exceptions.  IPR 
is not available to the patent owner, nor is it available to those who 
have previously sought to invalidate a claim of the at-issue patent 
through a civil action.72  Like PGR, the petitioner must also reveal 
the real party in interest.  Although narrower in scope, IPRs have 
quickly proved popular in terms of number of requests.73  IPRs have 
also been the focus of much writing.74 
 
 69  USPTO Fee Schedule, U.S. PATENT AND TRADEMARK OFFICE, 
https://www.uspto.gov/learning-and-resources/fees-and-payment/uspto-fee-
schedule (last visited Feb. 21, 2018) [https://perma.cc/FAA8-NDT6].  These fees 
were increased on January 16, 2018; Nathanael Luman & Kerry S. Taylor, USPTO 
to Increase IPR Fees by 33% and PGR Fees by 27% in 2018, KNOBBE MARTENS (Nov. 15, 
2017), https://www.knobbe.com/news/2017/11/uspto-increase-ipr-fees-33-and-
pgr-fees-27-2018 [https://perma.cc/FRM9-28AR]. 
 70  USPTO Fee Schedule, supra note 69.  This number does not include any 
litigation fees, merely the filing fee. 
 71 See 35 U.S.C § 311(b) (2012). 
 72 See id. at § 311(a), 315(a). 
 73 See Brian Love & Shawn Ambwani, Inter Partes Review: An Early Look at the 
Numbers, 81 U. CHI. L. REV. DIALOGUE 93, 93 (2014) (explaining that by late 2014, 
almost two thousand requests for IPR were filed since the new procedure launched 
in 2011). 
 74  See, e.g., Scott A. McKeown, PTAB Institution Rate Dips Into 60% Range, 
PATENTS POST-GRANT (July 22, 2014), http://www.patentspostgrant.com/ptab-
institution-rate-dips-into-60-range [https://perma.cc/2WXR-XJU8] (discussing 
the PTAB institution rates of IPR from February 2013 to July 2014); Michelle 
Carniaux & Michael E. Sander, Instituted Patent Claims Survive in About One Third of 
All IPR Trials, INTER PARTES REV. BLOG (Aug. 13, 2014), 
http://interpartesreviewblog.com/instituted-patent-claims-survive-one-third-ipr-
trials/ [https://perma.cc/72DV-E9SC] (calculating that the PTAB had issued 91 
Final Written decisions in IPR proceedings as of a little more than a year after the 
first was issued); Neal Solomon, The Problem of Inter-Partes Review (IPR), 
IPWATCHDOG (Aug. 8, 2017), http://www.ipwatchdog.com/2017/08/08/
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Even newer than the U.S. post-grant proceedings, the Japan 
Patent Office (JPO) reintroduced its post-grant proceedings in 2015 
after terminating the proceedings in 2003.75  This post-grant system 
is, at its core, the same as the opposition system that was terminated 
at the end of 2003.76 
Like in the European Union and the United States, anyone is 
permitted to utilize the Japanese opposition.  The Japanese 
opposition has the same option offered by the European opposition: 
the real party in interest may remain anonymous during the 
opposition proceeding.77  This is simply done by naming a shell 
entity instead.78  Yet unlike the European opposition, an opposition 
may only be filed with the JPO against an issued patent within the 
first six months, not nine months. 79   Moreover, also unlike the 
European opposition, the Japanese opposition has many grounds 
available to argue, including subject matter eligibility, novelty, 
enablement, and inventive step (the equivalent of non-obviousness 
in the United States).80  Again, with the priority date changed, often 
by one entire year, the patent’s subject matter, novelty, and 
nonobviousness are affected. 
The filing fees are extremely low for filing a Japanese opposition, 
requiring an initial filing fee of about the equivalent of $150 U.S., 
with an additional $22 U.S. for each challenged claim.81  Although 
foreign parties will likely need to incur translation fees, the Japanese 
opposition system is based only on documental evidence.82  There 
 
problem-inter-partes-review-ipr/id=86287/ [https://perma.cc/Z75K-STCK] 
(explaining some criticisms of IPR); Saurabh Vishnubhakat, Arti K. Rai, & Jay P. 
Kesan, Strategic Decision Making in Dual PTAB and District Court Proceedings, 31 
BERKELEY TECH. L.J. 45, 45 (2016) (analyzing the IPR process in relation to Article III 
patent litigation and the administrative state). 
 75  Miyako Saito & Manabu Hirata, Review of Current Status of Post-Grant 
Opposition System in Comparison with Invalidation Trial System, SEIWA PAT. & L. (Apr. 
29, 2016), http://www.seiwapat.jp/en/IP/pdf/en00027_PatentOpposition_vs._
InvalidationTrial.pdf [https://perma.cc/E23S-YXZH]. 
 76 PATENT OFFICE LITIGATION, supra note 55, at § 23:16. 
 77 PATENT OFFICE LITIGATION, supra note 55, at § 23:16. 
 78 PATENT OFFICE LITIGATION, supra note 55, at § 23:16. 
 79 PATENT OFFICE LITIGATION, supra note 55, at § 23:16. 
 80 PATENT OFFICE LITIGATION, supra note 55, at § 23:16. 
 81  Schedule of Fees, JAPAN PAT. OFF., https://www.jpo.go.jp/tetuzuki_e/
ryoukin_e/ryokine.htm [https://perma.cc/4X7H-G8ZM] (last visited Feb. 7, 2019).  
See also Overview of New Post-Grant Opposition System in Japan, SEIWA PAT. & L., 
http://www.seiwapat.jp/en/IP/20150407.html [https://perma.cc/J7ZR-LKV2] 
(last visited Feb. 7, 2019). 
 82 PATENT OFFICE LITIGATION, supra note 55, at § 23:24. 
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are no oral proceedings.  This helps to keep costs manageable, 
especially in regard to the parallel option of invalidation 
proceedings.83 
Notably, neither the European nor Japanese post-grant 
opposition systems have estoppel statutes.84  The lack of an estoppel 
statute stands in stark contrast to the post-grant system in the United 
States, creating two non-U.S. locations to, as patent practitioners 
have noted, “test competitor patent validity.”85 
In the United States, there are multiple estoppel statutes, with 
the following statute pertaining to the inter partes review:  
[t]he petitioner in an inter partes review of a claim in a 
patent . . . that results in a final written decision . . . may not 
request or maintain a proceeding before the Office with 
respect to that claim on any ground that the petitioner raised 
or reasonably could have raised during that inter partes 
review.86 
This means that in the United States, there is one opportunity to 
make arguments regarding a particular patent’s claims.  If a 
particular argument loses, or for strategic reasons a particular 
argument is not made, there is no second opportunity to try again.  
The petitioner is estopped from making the argument, although 
determining what the petitioner “raised or reasonably could have 
raised” is not without its own interpretation troubles.87 
However, in Europe and Japan, the lack of an estoppel statute 
means that if the petitioner loses on one or all of its grounds, it may 
 
 83 See PATENT OFFICE LITIGATION, supra note 55, at § 23:24. 
 84  See Karen E. Sandrik, The Post-Grant Life: Coordinating & Strategizing 
Challenges of Issued Patents in Multiple Continents, 102 CHI. -KENT J. INTELL. PROP. 449, 
455 (discussing the differences in post-grant systems of the United States, Japan, 
and the EU, and highlighting the lack of estoppel statutes in Japan and EU post-
grant proceedings). 
 85 Alastair Jones, The Gloves Are Off: Europe is the Location to Test Competitor 
Patent Validity, BARKER BRETTELL (Jan. 4, 2018) https://www.barkerbrettell.co.uk/
the-gloves-are-off-europe-is-the-location-to-test-competitor-patent-validity/ 
[https://perma.cc/56FK-RZ5D] (last visited Feb. 12, 2019).  See also International 
Post Grant Practice: Strategic Considerations Before the USPTO, EPO and CNIPA, 
INTELL. PROP. OWNERS ASS’N, https://www.ipo.org/index.php/ip-chat-channel/
ip-chat-channel-post-grant-proceedings/ [https://perma.cc/RD9D-UDAY] (last 
visited Feb. 12, 2019) (explaining “some have noted that in Europe and China, 
opposition can be used with little risk as a testing group for the presentation of 
arguments that could be used in litigation”). 
 86 35 U.S.C. § 315(e)(1) (2012). 
 87 See Sandrik, The Post-Grant Life, supra note 84, at 454-55. 
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repeat the same validity challenges in future proceedings.88  This 
makes opposition systems with no estoppel doctrine quite attractive 
as a testing ground for presentation of arguments.  With the 
combination of no estoppel statute, lower filing fee, ability to stay 
anonymous, and proceeding forward with well-known and tried 
system, there are relatively little downstream costs for parties to 
challenge their competitors’ patents. 
In this way, Europe has been the testing ground for challenging 
patents for some time now, as well as a patent holder’s willingness 
to litigate on multiple fronts to retain key features of the patent, such 
as breadth of claims and priority date.  The number of Japanese 
oppositions has been consistent for a few years, yet, for the reasons 
stated above, the post-grant proceedings present a strategic 
opportunity that companies will likely take advantage of as part of 
a global patent protection and enforcement policy. 
Following Japan’s example, Korea reintroduced its post-grant 
system in 2017, titling its new process “Request for Patent 
Cancellation.” 89   Korea had previously terminated its post-grant 
opposition system in 2007.90  In its earlier version, the post-grant 
process was only three months from the publication date of the 
patent, yet, with the new system, it is six months (like Japan’s patent 
opposition). 91   Similarly, anyone may file a request to cancel a 
patent, with grounds specifically including novelty, inventiveness, 
and priority.92  Although the fees are incredibly low, like in Japan—
just the equivalent of $10 U.S. per challenged patent—transactional 
fees (and local counsel) will quickly increase the total price.   
Finally, Korea does have an estoppel statute for all trial 
decisions, including a trial for cancellation, that prevents litigants 
from re-litigating a patent if an undesirable outcome occurs.93  In this 
 
 88 See Sandrik, The Post-Grant Life, supra note 84, at 455. 
 89 PATENT OFFICE LITIGATION, supra note 55, at § 23:46.  On the KIPO’s website, 
the translation actually comes out to “Application for Revoking Patent.”  Patent 
Act, Article 132-2 (Application for Revoking Patent) (2016), 
https://elaw.klri.re.kr/kor_service/lawView.do?hseq=42779&lang=ENG 
[https://perma.cc/FFD2-FL7K]. 
 90 PATENT OFFICE LITIGATION, supra note 55, at § 23:46 
 91 PATENT OFFICE LITIGATION, supra note 55, at § 23:46 
 92 PATENT OFFICE LITIGATION, supra note 55, at § 23:46 (showing that the priority 
challenge is technically listed under the “first-to-file rule” and the “expanded first-
to-file rule”). 
 93 See PATENT OFFICE LITIGATION, supra note 55, at § 23:62 (advising litigants of 
the broad estoppel created by an invalidation trial decision and for litigants to 
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way, Korean patent law resembles U.S. patent law more than 
Japanese patent law. 
Currently, there is no post-grant system available in China.94  
Instead, a petition to invalidate a patent goes through a litigation-
based system any time after the patent is granted.  This system is 
open to anyone wishing to challenge a post-grant patent.95   The 
official fee required to file a request for invalidation is around $475 
U.S.96 
Part 2, focused on U.S. law, and the next two parts, focusing on 
European and East Asian law, will explore particular laws regarding 
inventorship, ownership, and patent assignments.  There are several 
complicating factors here when looking at different laws.  One such 
complicating factor is the distinction between a common law 
country and a civil law country.  The United States is a common law 
country, with case law providing much guidance even when there 
is a statute.  Germany is a civil law country, with regulatory law and 
statutory law playing a much bigger role.  Handling issues of 
ownership and assignment through case law versus statute notably 
affects the struggle each independent country faces.  For the United 
States, it is how particular patent assignment law interprets 
particular words used in an effective, present assignment versus an 
ineffective assignment.  In other countries, including Germany, the 
Netherlands, and Japan, statutes provide much more guidance.  This 
creates more certainty but limits flexibility, which constrains parties 
and can lead to unnecessary inefficiencies. 
2. EMPLOYEE INVENTIONS & PATENT ASSIGNMENTS IN THE UNITED 
STATES  
The general rule in U.S. patent law is that the individual inventor 
owns what she creates.97  Following this general rule, U.S. patent law 
historically required that patent applications be filed in the name of 
the individual inventor.  Simply, “[a]n Application for patent shall 
 
“coordinate arguments and positions when there are invalidity proceedings in the 
other countries that involve the same family of patents”). 
 94 PATENT OFFICE LITIGATION, supra note 55, at § 23:71. 
 95 PATENT OFFICE LITIGATION, supra note 55, at § 23:72. 
 96 PATENT OFFICE LITIGATION, supra note 55, at § 23:72. 
 97 See Board of Trs. of Leland Stanford Junior Univ. v. Roche Molecular Sys., 
Inc., 563 U.S. 776, 785 (2011) (“Our precedents confirm the general rule that rights 
in an invention belong to the inventor.”). 
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be made, or authorized to be made, by the inventor . . . “98  The Patent 
Act explained that the applicant is the inventor: “The applicant shall 
make oath that he believes himself to be the original and first 
inventor of the process, machine, manufacture, or composition of 
matter, or improvement thereof, for which he solicits a patent . . . .”99 
Prior to the AIA, U.S. patent law had just a handful of exceptions 
to the general rule that the applicant is the same as the inventor.  
These exceptions included the death of the inventor, as well as if the 
inventor—obligated to assign her invention to another—either 
refused to participate in the filing of a patent application or could 
not be found or reached after “diligent effort.”100  In those instances, 
another party was permitted to file on behalf of the inventor, but not 
without a showing of an assignment, or an agreement to assign in 
writing, or that the filing without such a written record is 
nevertheless justified and necessary.101  In the latter instance, the 
person making the filing would also need to show a proprietary 
interest in the patent application, such as that she formally 
employed the inventor.  In this way, U.S. patent law has long 
required that the inventor be named in the application, even in the 
extraordinary circumstance that the inventor was not the actual 
applicant.102 
This pre-AIA practice of having the inventor, rather than the 
company, designated as the “Applicant” on patent applications is 
different when compared to other countries.  For example, the 
Federal Circuit Court of Appeals, the exclusive court of patent 
appeals in the United States, has explained that in “many foreign 
countries, unlike in the United States, the actual applicant for a 
 
 98 35 U.S.C. § 111 (2002) (pre-Leahy-Smith America Invents Act) (emphasis 
added). 
 99 35 U.S.C. § 115 (2013) (emphasis added). 
 100  See 35 U.S.C. § 118 (2002) (pre-Leahy-Smith America Invents Act) 
(explaining that if “an inventor refuses to execute an application for patent, or 
cannot be found or reached after diligent effort,” then another person may be able 
to file a patent application). 
 101 Id. (stating that the substitute application is limited to “a person to whom 
the inventor has assigned or agreed in writing to assign the invention or who 
otherwise shows proprietary interest in the matter justifying such action, may make 
application for patent on behalf of and as agent for the inventor on proof of the 
pertinent facts and a showing that such action is necessary to preserve the rights of 
the parties or to prevent irreparable damage”). 
 102 37 CFR 1.64 (pre-AIA) (explaining that the substitute statement must name 
the inventor, even when the inventor is not filing the patent application herself). 
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patent can be other than the inventor, e.g., an assignee.”103 Similarly, 
the Manual of Patent Examining Procedure (MPEP) warns: 
The requirement that the applicant for a patent in an 
application filed before September 16, 2012 be the 
inventor(s) . . . and that the inventor or each joint inventor be 
identified in applications filed on or after September 16, 
2012, are characteristics of U.S. patent law not generally 
shared by other countries.  Consequently, foreign applicants 
may misunderstand U.S. law regarding naming of the actual 
inventors causing an error in the inventorship of a U.S. 
application that may claim priority to a previous foreign 
application under 35 U.S.C. 119.104 
Because a goal of the AIA was to bring U.S. patent law closer to 
the rest of the world, this requirement was changed.  For all patents 
filed on or after September 16, 2012, the patent applicant no longer 
needs to be the same as the inventor.  Instead,”[a] person to whom 
the inventor has assigned or is under an obligation to assign the 
invention may make an application for patent.”105  Accordingly, a 
company may now be designated as the applicant, although the 
individual persons are still named as the inventors.106  Importantly, 
the AIA also included a change in law, that “[t]he original applicant 
is presumed to be the owner of an application for an original patent, 
and any patent that may issue therefrom in the absence of an 
 
 103 Bos. Sci. Scimed, Inc. v. Medtronic Vascular, Inc., 497 F.3d 1293, 1297 (Fed. 
Cir. 2007). 
 104 MPEP, supra note 27 at 2137.01. 
 105 35 U.S.C. § 118.  See also MPEP, supra note 27, at 605 (detailing this change 
in law):  
Effective September 16, 2012, the Office revised the rules of practice to permit a 
person to whom the inventor has assigned or is under an obligation to assign 
an invention to file and prosecute an application for patent as the applicant, and 
to permit a person who otherwise shows sufficient proprietary interest in the 
matter to file and prosecute an application for patent as the applicant on behalf 
of the inventor. See MPEP § 605.01 for information regarding the applicant in 
applications filed on or after September 16, 2012.  
For applications filed before September 16, 2012, a person to whom the inventor 
assigned an invention could file and prosecute an application for patent, but 
the inventor is considered the applicant.   
See MPEP § 605.02 (2015) for information regarding the applicant in applications 
filed before September 16, 2012.  
 106  See, e.g., U.S. Patent No. 10,212, 827 (filed July 21, 2016) (naming Intel 
Corporation as the “applicant” and the individual persons, presumably employees 
of Intel, as the “inventors”). 
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assignment.”107  Although the new statute regarding this change in 
practice does not state that the assignment must be in writing, it does 
retain that requirement elsewhere in the Patent Act.108 
U.S. patent law is clear that patent assignments must be in 
writing, but there is no statutory guidance on the language or 
contents of the assignment.  This means that employee inventors, 
and their respective assignments of any patentable inventions to 
their employers, are handled completely by common law. 
For example, in terms of assigning the specific priority right of a 
patent, U.S. patent law does not require that an assignment of a 
patent include an express statement also assigning the right of 
priority.  Simply, in U.S law, the priority right is regarded as part of 
the patent itself.  So while the Patent Act does mandate a patent 
assignment be in written form, there is no similar mandate 
regarding the particular contents of the assignment.109  Also, unlike 
other countries, U.S. patent law does not require, nor provide, any 
statutory suggestion requiring employers to compensate employees 
for their inventions.  Any assignment and, or, any form of additional 
compensation must be a contractual agreement between the parties. 
Before a formal recordation of an assignment from an inventor 
to assignee may be filed with the USPTO, it was, and remains after 
the AIA, a common practice for employees to enter into contractual 
agreements with their employers regarding the transfer of 
ownership of any patentable inventions made or conceived during 
employment.  This occurs after the individual inventor is designated 
as the “Applicant” in a patent application.  
Because a patent assignment is a contract, the Federal Circuit has 
historically applied the contract law of the relevant individual state 
when faced with an issue involving a patent assignment.110  The 
Federal Circuit has also previously stated that state courts should 
 
 107 MPEP, supra note 27, at 605.1 (2015).  
 108 See 35 U.S.C. § 261 (2012) (“Applications for patent, patents, or any interest 
therein, shall be assignable in law by an instrument in writing.”). 
 109  U.S. patent law does provide advantages to those who record patent 
assignments with the USPTO, namely protection against third party buyers or 
lenders.  See 35 U.S.C. § 261 (2012) (“An interest that constitutes an assignment, 
grant or conveyance shall be void as against any subsequent purchaser or 
mortgagee for a valuable consideration, without notice, unless it is recorded in the 
Patent and Trademark Office within three months from its date or prior to the date 
of such subsequent purchase or mortgage.”). 
 110 See, e.g., Euclid Chem. Co. v. Vector Corrosion Techs., Inc., 561 F.3d 1340, 
1343 (Fed. Cir. 2009) (applying Ohio state law after stating that “[c]onstruction of 
patent assignment agreements is a matter of state contract law”). 
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determine who owns the patent rights and on what terms. 111  
However, the Federal Circuit has, in recent years, also expressed 
that U.S. federal law, or more specifically “Federal Circuit law,” 
applies to certain instances.112  The Federal Circuit has explained 
that “[a]lthough state law governs the interpretation of contracts 
generally . . . , the question of whether a patent assignment clause 
creates an automatic assignment or merely an obligation to assign is 
intimately bound up with the question of standing in patent cases.  
We have accordingly treated it as matter of federal law.”113  
U.S. patent law clearly states that “[i]nventions may be assigned 
before they are patented.”114  Moreover, U.S. patent law also clearly 
states that “[a]n assignment of an expectant interest can be a valid 
assignment.”115  However, until the employee does indeed create or 
conceive of patentable technology, “the assignee holds at most an 
equitable title.”116 
Equitable title is distinct from legal title in U.S. patent law.  For 
example, equitable title is not a sufficient title to bring a suit for 
patent infringement; one must have legal title to bring a suit for 
patent infringement and seek damages.117  This “expectant interest,” 
also known as a future interest, is created when there is an 
assignment that is made prior to the actual existence of an 
invention.118  It is called an expectant interest because the employee 
and the employer are expecting that the employee creates or 
 
 111 See, e.g., Jim Arnold Corp. v. Hydrotech Sys., 109 F.3d 1567, 1572 (Fed. Cir. 
1997) (“It may seem strange at first blush that the question of whether a patent is 
valid and infringed ordinarily is one for federal courts, while the question of who 
owns the patent rights and on what terms typically is a question exclusively for 
state courts. Yet that has long been the law.”). 
 112 See Intellectual Ventures I L.L.C v. Erie Indemnity Co., 850 F.3d 1315, 1320, 
fn. 1 (Fed. Cir. 2017). 
 113 DDB Techs., L.L.C. v. MLB Advanced Media, L.P., 517 F.3d 1284, 1290 (Fed. 
Cir. 2008) (citations omitted).  Despite some inconsistencies in this jurisprudence, it 
is now generally understood in the United States that Federal Circuit law governs 
the interpretation of the type of patent assignment at issue in the present case.  Still, 
because of these inconsistencies, district federal courts do sometimes look to state 
law for guidance when interpreting patent assignments.  See, e.g., Affymetrix, Inc. 
v. Illumina, Inc., 446 F. Supp. 2d 292, 296 (D. Del. 2006) (concluding no Federal 
Circuit opinion was directly relevant to the language in the at-issue expectant 
interest clause and, therefore, it was proper for the court to look to California state 
contract law for guidance). 
 114 Cammeyer v. Newton, 94 U.S. 225, 226 (1876). 
 115 FilmTec Corp. v. Allied-Signal, Inc., 939 F.2d 1568, 1572 (Fed. Cir. 1991). 
 116 Id. 
 117 See Arachnid, Inc. v. Merit Indus., Inc., 939 F.2d 1574, 1579 (Fed. Cir. 1991). 
 118 See FilmTec Corp. v. Allied-Signal, Inc., 939 F.2d 1568, 1572 (Fed. Cir. 1991). 
Published by Penn Law: Legal Scholarship Repository,
784 U. Pa. J. Int'l L. [Vol. 41:3 
conceives a patentable invention at some point in the future during 
her employment.  Because of this expectation of the creation of 
patentable technology, the parties are planning ahead by assigning 
the expectant interest in any future inventions by way of a patent 
assignment clause.  This patent assignment clause is often a part of 
a larger employment agreement.  Assigning future rights in this way 
is permitted under U.S. law. 
When an employee assigns an expectant interest to an employer, 
one of two situations can occur.  The first situation is one in which 
the expectant interest clause immediately changes into an 
“automatic” or “immediate” assignment; that is, an assignment 
transfers legal title to the employer without any further conveyance 
or action needed by either party.  As soon as the employee creates 
an invention, the employer enjoys legal title to that invention.  The 
second situation is one in which the expectant interest clause does 
not immediately transfer legal title once the employee creates an 
invention.  Instead, the employer, the assignee, remains with just 
equitable title.  This is often termed an “agreement to assign” or 
“obligation to assign.”  Thus, the second situation does not result in 
the immediate conveyance of equitable-to-legal title, like that which 
occurs with an automatic assignment.  In this second situation, the 
employee has only agreed to assign her invention, meaning the 
employer starts with equitable title and ends with equitable title 
until some future act of conveyance in writing takes place 
transferring legal title to the employer.119 
The creation of an assignment that conveys automatic and 
immediate ownership compared to a mere obligation to assign 
ownership at some future point depends upon the language used by 
the parties. 120   Accordingly, the parties distinguish between an 
immediate assignment and an obligation to assign a close analysis 
of the language.  This is important, as this law distinguishes the 
United States from much of the world.  This unique law, one that 
hinges on very particular language, is at issue in seemingly almost 
 
 119 Compare FilmTec Corp. v. Allied-Signal, Inc., 939 F.2d 1568, 1573 (Fed. Cir. 
1991) (finding expectant interest clause language “agrees to grant and does hereby 
grant” creates an automatic assignment), with Arachnid, Inc. v. Merit Indus., Inc., 
939 F.2d 1574, 1580 (Fed. Cir. 1991) (finding expectant interest clause language “all 
rights thereto will be assigned” as merely an “agreement to assign, not an 
assignment”) (emphasis removed). 
 120 See DDB Techs., L.L.C. v. MLB Advanced Media, L.P., 517 F.3d 1284, 1290 
(Fed. Cir. 2008) (explaining “whether an assignment of patent rights in an . . . is 
automatic, requiring no further act on the part of the assignee, or merely a promise 
to assign depends on the contractual language”). 
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every post-grant European Opposition where the opposition is 
challenging the chain of title of the patent that is based on U.S. 
priority. 
As stated above, an automatic assignment occurs when the 
contract expressly grants rights in future inventions.  There is no 
further act of conveyance needed to effectuate legal title to the 
assignee.  The Federal Circuit has held that an automatic assignment 
was created when the parties stated that the employee “‘agrees to 
and does hereby grant and assign’ all rights in future inventions.”121  
When using this present conveyance language, the parties seem to 
intend no further action is necessary to effectuate the transfer of 
legal title from the employee to the employer.122  With the automatic 
transfer of the expectant interest, while the individual inventor does 
still claim inventorship and most often will designate herself as 
“Applicant” pursuant to U.S. law, and had to prior to the AIA, legal 
ownership is already with the employer.123 
In contrast, when the parties use language that seems to speak 
of a future event happening, the Federal Circuit has held that the 
parties created only an agreement to assign.  For example, an 
agreement to assign is conveyed with the following language: “[a]ny 
inventions conceived by [Company] or its employees . . . in the 
course of the project covered by this agreement, shall by the 
property of [Client], and all rights thereto will be assigned by 
[Company] to Client.” 124   This “will be assigned” conveyance 
language implies that the parties had not intended for the 
 
 121 Id. at 1290. 
 122  See also Imatec, Ltd. V. Apple Computer, Inc., 81 F. Supp. 2d 471, 482 
(S.D.N.Y. 2001), aff’d 15 F. App/x 887 (Fed. Cir. 2001) (quoting the Invention 
agreement which states “I agree to assign, and hereby do assign to [Company] . . . 
all my rights to inventions which I have made or conceived . . . .”); SIRF Tech., Inc. 
v. Int’l Trade Comm’n, 601 F.3d 1319, 1326 (Fed. Cir. 2010) (“[t]he Employee assigns 
all of his or her right, interest, or title in any Invention to the Employer to the extent 
allowed by law.”); Preston v. Marathon Oil Co., 684 F. 3d 1276, 1288 (Fed. Cir. 2012) 
(“Because the assignment clause in the April Employee Agreement states that the 
employee agrees to ‘hereby assign’ all ‘Intellectual Property,’ it is an express 
assignment of rights in future inventions that automatically assigned rights to 
[Company] without the need for any additional act.”); AgroFresh Inc. v. MirTech, 
Inc., 2017 WL 2829627, *13 (D. Del. 2017) (holding that “[Company] hereby assigns 
automatically all rights, and all future rights, . . .”  is an “assignment [that] is effected 
at the moment the” invention is made) (emphasis in original). 
 123 See Israel Bio-Engineering Project v. Amgen, Inc., 475 F.3d 1256, 1263 (Fed. 
Cir. 2007) (explaining “issues of patent ownership are distinct from questions of 
inventorship”). 
 124 Arachnid, Inc. v. Merit Indus., Inc., 939 F.2d 1574, 1576 (Fed. Cir. 1991) 
(emphasis added). 
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assignment to occur without some further act of conveyance in the 
future. 125   Another example of an expectant interest clause that 
merely obligates the employee to convey an assignment of her 
creations at a future date reads: 
Such Proprietary Developments are the sole property of 
[Company], and I agree: 
a. to disclose them promptly to [Company]; 
b. to assign them to [Company]; and 
c. to execute all documents and cooperate with HP in all 
necessary activities to obtain patent, copyright, mask work, 
and/or trade secret property in all countries, [Company] to 
pay expenses.126 
With this expectant interest clause, the Federal Circuit 
determined that the multiple actions contemplated by the parties, 
“to disclose,” “to assign,” and “to execute,” demonstrated their 
intent for the employee to have obligations to take these actions, not 
that legal title would automatically vest in the employer once the 
employee conceived of an invention. 
The language that expresses the agreement to assign is not 
significantly different than that used in an automatic assignment.  
Indeed, Justice Breyer has expressed in a U.S. Supreme Court 
opinion his concern that “[g]iven what seem only slight linguistic 
differences in the contractual language, this reasoning seems to 
make too much of too little.”127  At this moment, the Supreme Court 
has not taken the opportunity to reconsider this doctrine and 
potentially overrule or alter it.  Because of the small variance in the 
language, federal courts are often faced with very difficult 
interpretations of expectant interest clauses.  This is especially true 
because the very nature of this type of patent assignment seems to 
necessarily invoke the use of words like “shall” and “will” when 
talking about something that is in the future. 
Moreover, parties often combine present language with that of 
future conveyance language, as there are several stages of the 
patenting process that may require that the employee take further 
 
 125 Id. (emphasis added). 
 126 IP Venture, Inc. v. Prostar Computer, Inc., 503 F.3d 1324, 1326 (Fed. Cir. 
2007). 
 127 See Board of Trs. of Leland Stanford Junior Univ., supra note 97, at 2202-03 
(Breyer, J., dissenting).  
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actions.  When this occurs, it makes the interpretation of the patent 
assignment more difficult, thereby opening the door for the court to 
decide the outcome (as opposed to the parties in the first instance). 
For example, take the following language: “‘Bios hereby conveys, 
assigns, transfers and delivers to [Agribiotics, Inc.] all of its right, title, 
estate and interest to all its property, assets, business and 
undertaking, both real and personal, movable and immovable, 
wherever situate [sic] . . . .’” 128   This italicized language seems 
similar to the automatic assignment language seen in other opinions 
such as FilmTec Corp. or DDB Techs, Inc., yet the dissolution 
agreement between the parties also called for Bios to provide any 
necessary documentation “for more effectively and completely vesting 
the property and assets conveyed . . . or for the purpose of 
registration or otherwise.”129 
In interpreting these two clauses together, the court determined 
that the language in the dissolution agreement was “suggest[ing] 
only that Bios will perform any ministerial tasks necessary to 
effectuate the transfer of its assets.” 130   Finding the parties had 
created an automatic assignment, the court then explained that the 
language obligating the assignee to take further steps “does not 
undermine the conclusion that the dissolution was a present 
assignment of assets to Agribiotics Inc.”131  So despite the language 
of “effectively and completely vesting,” no further action was 
necessary to create a legally cognizable interest when the invention 
was created.  There was only the recognition by the parties that more 
paperwork in the future would likely be necessary.  And while not 
citing directly to the applicable state law, for both parties had agreed 
federal law controlled this issue, the state law did favor the 
approach taken here to carefully ascertain the intent of the parties.132 
 
 128 EMD Crop Bioscience Inc. v. Becker Underwood, 750 F. Supp. 2d 1013 
(W.D. Wis. 2010) (emphasis added). 
 129 Id. at 1014 (emphasis added). 
 130 Id. 
 131 Id. 
 132  See Tufail v. Midwest Hosp., LLC, 833 N.W.2d 586, 592 (Wis. 2013) 
(“Contract interpretation generally seeks to give effect to the parties’ intentions.”).  
When parties cite to state law, or when the federal court feels like it needs further 
guidance given the ambiguity of the agreement, employing state contract law or 
general principles of contract law may be appropriate.  See St. Clair Intellectual 
Property Consultants, Inc. v. Palm, Inc. 2009 WL 1220546 (D. Del. May 4, 2009) 
(using both present conveyance language and agreement to assign conveyance 
language, and where the court used general principles of contract law and Federal 
Circuit law to interpret such language). 
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In summary, while the individual state law usually governs the 
interpretation of contracts, whether the assignment of patent rights 
under an expectant interest clause is an automatic assignment or 
merely an agreement to assign is a matter of Federal Circuit law.  
Federal courts applying Federal Circuit law look closely at the 
contractual language used by the parties.  And if the at-issue 
language seems to expressly convey present rights in future 
inventions, no further act of conveyance is required once an 
invention is created.  The transfer of legal title occurs immediately 
by the operation of law.  In contrast, if the language in the expectant 
interest clause explains that the parties intend for the inventor to 
take further steps to convey legal ownership, such as agreeing to 
cooperate and execute paperwork to establish ownership, this is 
merely an agreement to assign.  There is no transfer of legal title; 
some other act of conveyance is necessary before legal title is 
transferred from employee to employer. 
3. EMPLOYEE INVENTIONS & PATENT ASSIGNMENTS IN EUROPE 
When comparing U.S. patent assignment law, most notably in 
the employer-employee context, to corresponding law around the 
world, there are a couple questions to ask in every instance.  First, 
does the respective country require, like the United States does, that 
the inventor be identified in the patent application?  This may occur 
by the inventor being the same as the applicant, as is often the case 
in the United States, or as the inventor but not the applicant and, or, 
owner of the patent.  This latter situation is now permitted in the 
United States.  Second, what is the general rule regarding whether 
an employer or the employee owns the invention?  In the United 
States, the employee generally owns the invention, yet employees 
and employers often enter into patent assignment agreements prior 
to the creation of any patentable inventions.  This causes the 
employee’s ownership interests to either automatically vest in the 
employer upon creation of the invention, or with some further act of 
conveyance.  These next two subparts will explore the answers to 
these two questions in two different countries: Germany and The 
Netherlands. 
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3.1. The German Approach 
In Germany, as well as under the European Patent Act, the 
general rule of patent entitlement is that it shall belong to the 
inventor.133  Moreover, only an individual, a natural person, is able 
to make the creative contribution necessary to entitle one to a 
patent. 134   In this way, a legal entity, a company, cannot be an 
inventor under German law.135 
That said, it is estimated that between eighty to ninety percent 
of all patented inventions in Germany are created by employees.136  
Intending to provide rules for balancing the interests under patent 
law and labor and employment law for employees-inventors and 
employers, Germany has enacted the Employees’ Inventions Act 
(ArbEG).137  Most notably, the ArbEG provides employers the ability 
to secure ownership of inventions made by their employees, while 
also balancing the employees’ interest to reasonable 
compensation.138 
Under the ArbEG, the general rule holds true: the initial inventor 
is the owner.139  Instead of using patent assignment law, through the 
form of contract, like the United States does, to change this 
ownership, the ArbEG contains a provision providing employers 
the right to claim either the transfer of ownership or an exclusive 
license to use the invention.140  Not only is there no need to contract 
 
 133  See Patentgeseta [PatG] [Patent Act], Dec. 16, 1980, Bundesgesetzblatt 
[BHBI] at 501, §6 (Ger.) [hereinafter German Patent Act].  See also European Patent 
Convention (EPC), Article 60(1): “The right to a . . . patent shall belong to the 
inventor or his successor in title.” 
 134 As one author stated: “Because an invention comes from a human being, 
an inventor cannot be a legal entity.” Alexander Harguth, Patent Ownership in 
Germany: Employers v. Employees, MCDERMOTT WILL & EMERY (July 2013), 
https://www.jdsupra.com/legalnews/patent-ownership-in-germany-employers-
v-83560/ [https://perma.cc/43RN-33SZ].  
 135 Id. 
 136 Sebastian Wündisch, Employee-Inventors Compensation in Germany—Burden 
or Incentive?, 52 LES NOUVELLES - J. LICENSING EXECUTIVES SOC’Y 105 (2017).  
 137  See Arbeitnehmererfindungesetz, [ArbEG] [Employees’ Inventions Act] 
(July 31, 2009) (English translation available at http://www.wipo.int/wipolex/
en/text.jsp?file_id=229680#LinkTarget_642 [https://perma.cc/P8VP-2W3B]).  See 
also Toshiko Takenaka, Serious Flaw of Employee Invention Ownership Under the Bayh-
Dole Act in Stanford v. Roche: Finding the Missing Piece of the Puzzle in the German 
Employee Invention Act, 20 TEX. INTELL. PROP. L.J. 281, 284 (2012). 
 138 See ArbEG, supra note 137, at §§ 6, 9. 
 139 Takenaka, supra note 137, at 314. 
 140 See ArbEG, supra note 137, at 19, § 6. 
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in the way that employers do in the United States, but any contract 
that conflicts with the ArbEG is simply void.141 
The ArbEG also clearly defines the scope of this statute and the 
inventions that fall under it.  There are two types of inventions: 
service inventions and free inventions.142  A service invention is one 
made or conceived from the employee’s tasks within the scope of 
the employer’s business, or, more generally, public 
administration.143  A free invention is defined as anything other than 
a service invention.144 
In practice, for all service inventions, the statute works to create 
an obligation on the employee to immediately report any and all 
inventions to her employer, or at least “without undue delay.”145  
This reporting requires a detailed description of the invention that 
is sufficient for one to understand how and why the invention was 
made.146  Upon this reporting, a four-month period is triggered.147  
The employer then has four months to decide whether to claim the 
invention or not.148  This is an “opt out” period of sorts.  In short, if 
the employer misses this deadline, the invention is nevertheless 
deemed claimed by the employer.  Thus, the employer has to 
actively opt out of claiming any patentable invention by its 
employees.  This is a rather recent shift in the statute, with pre-2009 
law requiring the employer to actively claim the employee’s 
invention.149   In this way, the former approach was an “opt-in” 
approach.150 
For free inventions, which should likewise be disclosed like 
service inventions upon conception, the employee does not have the 
same burden of a detailed report.  That said, the employee does need 
 
 141 ArbEG, supra note 137, at § 22. 
 142 ArbEG, supra note 137, at § 4(1). 
 143 ArbEG, supra note 137, at § 4(2).  More technically, “[a]n invention made 
during a term of employment is a service invention if (1) it resulted from the 
employee’s tasks in the employer’s business or public administration, or (2) it is 
essentially based upon the experience or activities of the employer’s business or 
public administration.”  Takenaka, supra note 137, at 315. 
 144 ArbEG, supra note 137, at § 4(3). 
 145 ArbEG, supra note 137, at § 5. 
 146 ArbEG, supra note 137, at § 4(2). 
 147 ArbEG, supra note 137, at § 5. 
 148 ArbEG, supra note 137, at § 5. 
 149 See Wündisch supra note 136, at 105 (explaining this “opt-in” approach was 
riddled with errors in practice and prompted the recent change). 
 150 See Wündisch supra note 136, at 105. 
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to, in essence, adequately explain why the invention falls outside the 
scope of her employment.151 
Similar to other countries’ patent law, like other countries within 
the European Union, 152  as well as Argentina, Hong Kong, and 
Korea,153 the ArbEG provides that an employee inventor is entitled 
to reasonable compensation, additional to her normal salary, when 
her employer claims her invention and uses it.154  Note, that this 
right of additional compensation only arises upon the employer’s 
use of the patented technology.155  The claim for payment occurs 
three months after this first use, and continues for the life of the 
patent.156  If the patent is invalidated at some point, payments made 
to the employee may not be reclaimed by the employer.157 
The valuation of this compensation is on a case-by-case basis, 
with factors such as the commercial application of the invention, 
level of employee contribution and position within the company, 
playing a role in determining the reasonable compensation. 158  
Moreover, the Guidelines on the Compensation of Employee 
Inventions offers a complex formula that takes into account different 
fields, from electrical to chemicals and pharmaceuticals.159   And, 
finally, for some industries, such as academia, there is a flat rate, 
which is taken from the licensing or other income of the patentable 
invention, used to simplify and streamline the remuneration 
process. 160   Overall, while there is debate regarding whether 
Germany’s regulatory approach to compensation of patentable 
 
 151 See ArbEG, supra note 137, at § 18(1). 
 152  Other countries in the European Union similarly have remuneration 
statutes, including the Netherlands, Finland, Italy, and Spain.  See Scott Foley et al., 
Thinking Globally: Inventor Remuneration Rights, LANDO & ANASTASI (Dec. 8, 2017), 
http://www.lalaw.com/news_resources/thinking-globally-inventor-
remuneration-rights/ [https://perma.cc/NC9K-6QZ9]. 
 153 See id.  See also Orly Lobel, The New Cognitive Property: Human Capital Law 
and the Reach of Intellectual Property, 93 TEX. L. REV. 789, fn. 148 (2015) (“Germany, 
the United Kingdom, France, and Finland all require fair compensation to the 
employee for any assigned invention” and “China and Japan similarly guarantee 
employee-inventions a reward for assigned work.”). 
 154 See ArbEG, supra note 137, at § 9(1). 
 155 See ArbEG, supra note 137, at § 9(1). 
 156 See Wündisch supra note 136, at 106. 
 157 See Wündisch supra note 136, at 106. 
 158 See Wündisch supra note 136, at 106. 
 159 See ArbEG, supra note 137, at § 9(1). 
 160 See Wündisch, supra note 136, at 109 (explaining “German law has a special 
provision granting the university inventor a flat rate of 30 percent of the income 
from the utilization proceeds of the university”). 
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inventions in the employment context provides desirable incentives 
that lead to maximum creativity and ingenuity, empirical research 
has confirmed “that the law creates substantial monetary rewards 
for productive inventors.”161 
3.2. The Dutch Approach 
The Dutch Patent Act of 1995 governs patent assignments, 
including those assigned in the employer-employee relationship, via 
statute.162  The language of Article 12.1 states the general rule: the 
employee-inventor is the entitlement owner.163  The exception to this 
general rule is when the nature of the employee’s job is to make 
inventions of the type at issue.  Let’s call this the “employee 
exception.”  In full:  
If the invention for which a patent application has been filed 
has been made by a person employed in the service of 
another party, the employee shall be entitled to the patent 
unless the nature of the service entails the use of the 
employee’s special knowledge for the purposes of making 
inventions of the same kind as that to which the patent 
application relates, in which case the employer shall be 
entitled to the patent.164 
There are some patent commentators that feel the opposite is 
true: that actually the general rule is that the employer is the owner 
of the patent, with the exception that the employee might own the 
 
 161 Dietmar Harhoff & Karin Hoisl, Institutionalized Incentives for Ingenuity—
Patent Value and the German Employees’ Inventions Act, 36 RES. POL’Y 1143 (2007), 
https://www.sciencedirect.com/science/article/pii/S0048733307001497 
[https://perma.cc/2GAL-ZMLM]. 
 162 Patent Act 1995 (Rijksoctrooiwet 1995) [hereinafter Patent Act 1995], the 
unofficial translation is available at https://www.ivir.nl/syscontent/pdfs/163.pdf 
[https://perma.cc/R3SB-4KZY]. 
 163 Id. at Article 12.1.  This entitlement is for both the patent application and 
resulting patent.  See also The International Association for the Protection of 
Intellectual Property, Netherlands Report Q183, at 6 [hereinafter AIPPI], 
[https://perma.cc/8X5M-CSHN] (explaining the courts’ application of Article 
78.1 of the Patent Act, which states that ownership of the patent can be claimed by 
the person who is entitled to the patent based on Article 12 of the Patent Act). 
 164 See Patent Act 1995, supra note 162, at Article 12.1. 
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invention.165  Presumably, this opinion comes from the observance 
that in many instances, the employee at question will be hired 
specifically to create or be a part of a team that creates innovation.  
Moreover, practitioners do not want the employer to need to get a 
separate agreement from the employee, which “may lead to 
difficulties, e.g., when the employee cannot be traced or refuses to 
co-operate with such a transfer.”166 
Two examples of this occurred, at least in part, due to the pre-
AIA U.S. law requiring that employees/inventors serve as the 
applicants of U.S. patent applications.  In these two examples, an 
employee refusing to execute documents needed to assign U.S. 
patent applications to the employer.167  This serves as another reason 
that international harmonization is so important.  It is hard to trace 
the chain of title when there are different requirements on which 
party must serve as the applicant, which may or may not be the same 
as the owner from one country to another. 
Beyond the traditional employer/employee context, the Dutch 
Patent Act contains a similar provision for patents created “in the 
context of training course,”—the trainee exception, and for patents 
in the field of research or service at a university, college or research 
institution—the researcher exception.  In the training exception, “the 
party for whom the services are performed shall be entitled to the 
patent[,] unless the invention has no connection with the subject of 
the services.”168  In the researcher exception, the statute, in essence, 
assumes that the invention was made pursuant to one carrying out 
“research in the service of a university, college or research 
establishment, [then] the university, college or research 
establishment shall be entitled to the patent.”169 
 
 165 See AIPPI, supra note 163, at 15 (explaining “the group is of the opinion 
that if the requirements for entitlement of the employer to the in-tellectual 
property rights in the employee’s creation have been fulfilled (e.g. the 
requirement that making creations like the creation in question must have been 
part of the employee’s employment), the employer should be the owner of the 
intellectual property rights from the outset.”). 
 166 AIPPI, supra note 163, at 15. 
 167 See AIPPI, supra note 163, at 15. 
 168 See Patent Act 1995, supra note 162, at Article 12.2. 
 169 See Patent Act 1995, supra note 162, at Article 12.3.  Note here that “Article 
12 makes a distinction between employees in the private sector (article 12.1: entitled 
to their inventions unless the making of such inventions was part of the 
employment) and researchers at a university or research institute (article 12.3: 
inventions made by these researchers always belong to the university or research 
institute)”.  AIPPI, supra note 163, at 10. 
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Finally, the Dutch Patent Act also permits parties to change, 
pursuant to a written agreement, the general rule of Article 12.1, as 
well as its exceptions and the provisions regarding inventions made 
connected to training courses and research.170  These rules all govern 
what we would term “employees” in the United States, that is, not 
independent contractors. 171   These provisions specifically cover 
employees who have an employment contracts, as meant in the 
Dutch Civil Code, and to civil servants employed by the government 
or other public institutions, such as a public university or research 
institution.172  If an employee does not have a contract, then the 
default rule applies: the employee enjoys the rights to her 
inventions. 173   Accordingly, parties and courts must look to the 
agreement to determine the scope of one’s employment and 
expectation regarding future inventions.  If parties simply use 
language that invokes the Dutch Patent Act, there will not be the 
parsing of language like there is in the United States.  Indeed, there 
are “few disputes . . . brought before the court” regarding patent 
ownership and use of rights over inventions made or conceived in 
the workplace.174 
Two rules that parties are not permitted to opt out of or change 
via contract, are the right as an inventor to be identified as such in 
the patent application and the remuneration statute.  Like in the 
United States and elsewhere, the inventor has a right to be identified 
as the inventor. 175   While in the United States, this right is not 
 
 170  See Patent Act 1995, supra note 162, at Article 12.5 (“The provisions of 
paragraphs (1), (2) and (3) may be departed from by written agreement.”). 
 171 See Wouter Pors, Employee Inventions in The Netherlands, Y.B. LES 
NOUVELLES 117, 118 (June 2017), http://birdbuzz.nl/wp-
content/uploads/2017/07/2017-07-Pors-Employee-Inventions-In-The-
Netherlands.pdf [https://perma.cc/D9VD-AFMT]  (stating that the employee 
exception “doesn’t cover free lancers, self-employed workers or managers who 
don’t have an employment contract (but for instance a management contract 
between their personal legal entity and the company)”. 
 172 Id. 
 173 Id. 
 174 AIPPI, supra note 163, at 13. 
 175 See Patent Act 1995, supra note 162, at Article 14 (“Any person who has 
made an invention for which a patent application has been filed, but who cannot 
claim any title to a patent on the ground of Article 12(1), (2) or (3) or under an 
agreement concluded with the applicant or his predecessors in title, shall have a 
right to be named as the inventor in the patent.”). 
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attributed as a “moral” right, it is commonly so throughout 
Europe.176 
Also, somewhat common in Europe is the remuneration statute 
in the Dutch Patent Act regarding employee compensation for 
patents.  This remuneration statute covers the employee, trainee, 
and research exceptions: where the “employer” is entitled to the 
patent, not the inventor.  Article 12.6 states that 
In the event that the inventor cannot be deemed to have been 
compensated in the salary he earns or the pecuniary 
allowance he receives or in any extra remuneration he 
receives for not having been granted a patent, the party who 
is entitled to the patent on the basis of paragraphs (1), (2) or 
(3) will be obliged to grant him equitable remuneration 
related to the pecuniary importance of the invention and the 
circumstances under which it was made.  Any right of the 
action on the part of the inventor in accordance with this 
paragraph shall lapse after the expiry of three years from the 
date of the grant of the patent.177 
As to the determination of whether an employee/inventor 
should receive extra compensation, that beyond the employee’s 
normal wages, is one that seems troubling on the surface, but is not 
as much in practice.  The Supreme Court has, on at least two 
occasions, stepped in to clarify and provide guidance to Article 
12.6.178  In both opinions, the Supreme Court held that the invention 
created was within the scope of the employee’s employment, 
thereby supporting the conclusion that the employee’s normal 
wages cover the possibility of a patentable invention.  It is only in 
the “exceptional circumstances [that] [] the employee [will] be 
entitled to additional compensation.”179 
 
 176 See AIPPI, supra note 163, at 1-2 (explaining that is a “mandatory” rule and 
a “(moral) right of the employee to be mentioned as the inventor in the patent”). 
 177 See Patent Act 1995, supra note 162, at Article 12.6 translated in Patent Act 
1995, Netherlands Enterprise Agency (Sept. 18, 2009), 
https://english.rvo.nl/topics/innovation/patents-other-ip-rights-topic/patent-
law/patent-act-1995 [https://perma.cc/2ZKR-F4VR]. 
 178 AIPPI, supra note 163, at 6 (identifying two cases, including a claim for 
compensation of the employee and a decision of a public entity regarding 
compensation). 
 179 AIPPI, supra note 163, at 11. 
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4. EMPLOYEE INVENTIONS & PATENT ASSIGNMENTS IN EAST ASIA 
Similar to the two parts above, this part will detail who has the 
first right to the patent, the inventor or the company, in Japan, 
Korea, and China.  In the case that there needs to be a patent 
assignment, this part will also describe the patent assignment laws 
that are unique to each country. 
4.1. The Japanese Approach 
Unlike in the United States, where, at least until very recently, 
most patent applicants are the inventor, in Japan, most patent 
applicants are the assignees, not the inventors.180  Seeking to address 
a myriad of shortfalls in its employee invention law under the 
Japanese Patent Act,181 amendments were made in 2004 and 2015, 
effective on April 1, 2016, to the employee inventions statute. 182  
Japanese patent law is more like that of Germany and Netherlands, 
than the United States, in that its statutory law seeks to answer many 
of the basic questions of inventorship and ownership in the first 
instance. 183   It is also like Germany and others in that only an 
 
 180 Mary LaFrance, A Comparative Study of United States and Japanese Laws on 
Collaborative Inventions, and the Impact of Those Laws on Technology Transfers, 2005 
INST. INTELL. PROP. BULL. 86, 91 (2005), http://scholars.law.unlv.edu/cgi/
viewcontent.cgi?article=1435&context=facpub [https://perma.cc/9ESR-XPF6] 
(stating that “patent applicants in Japan are typically not the actual inventors, but 
their assignees”). 
 181 See Tokkyoho Patent Act [hereinafter Tokkyoho Patent Act], Law No. 121 
of 1959, Art. 35, translated in Patent Act (Act No. 121 of 1959), 
http://www.cas.go.jp/jp/seisaku/hourei/data/PA.pdf 
[https://perma.cc/PEU9-S9KC], the unofficial translation is available at 
http://www.japaneselawtranslation.go.jp/law/detail/?printID=&ft=1&co=01&x
=32&y=19&ky=%E7%89%B9%E8%A8%B1%E6%B3%95&page=10&id=42&lvm=&
re=02&vm=02 [https://perma.cc/DCF3-39FW].  This foundation remains in 
today’s law.  For example, Article 35 of the Japanese Patent Act of 1959 stated that 
when an employee obtained a patent, an employer enjoyed a non-exclusive 
license.  Article 35 was amended to, most notably, address the remuneration 
portion of the statute.  See also Takashi Suzuki, Progress Report: Amendment of 
Article 35 (employee invention) of the Japanese Patent Act, JAPAN INTELL. PROP. ASS’N 4 
(Apr. 22, 2015), http://www.jipa.or.jp/english/activities/others/pdf/
150422JIPA-AIPLA%20Meeting.pdf [https://perma.cc/A827-RNN6]. 
 182 See generally Tokkyoho Patent Act, supra note 181. 
 183 See generally Tokkyoho Patent Act, supra note 181. 
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individual, a natural person, can be the inventor.184  Accordingly, the 
general rule is that patent ownership is first vested with the 
individual inventor.  The fact that most applicants are not the 
inventors demonstrates the high importance of patent assignment, 
either via statute or common law, in Japan. 
Article 35, the employee inventions statute, has five subsections.  
The first subsection is unchanged from the former law.  Most simply, 
if the employee-inventor receives a patent that is within the scope of 
her employer’s business, then the employer has a royalty free, non-
exclusive license to the patent.  Like Germany and Netherlands, this 
law applies to both private and public industries.185   
The second subsection then explains that an invention made by 
an employee that is not captured within the first subsection because 
it is, in essence, outside the scope of the employee’s work, it does not 
automatically vest in the employer, nor can it be assigned ex ante to 
the employer.  In fact, any such “contractual provision . . . providing 
in advance that the right to obtain a patent for such an invention 
shall belong to the employer . . . shall pass to the employer, etc. or [] 
shall have a provisional exclusive license or exclusive license on 
such an invention shall be null and void.”186  This section is largely 
unchanged from the former statute, with simple language added for 
clarification.  This section makes sense as it carves out inventions 
made by employers that are presumably conceived on their own 
time and outside the scope of their job.  Of course, what does and 
does not “correspond to an employee invention” is not necessarily 
clear cut.  The next section briefly discusses what does “correspond 
to an employee invention”,  a 2015 amendment.   
This third subsection explains that when an invention is made 
by an employee that does, in fact, correspond to an employee 
invention, it can be assigned to the employee prior to the conception 
 
 184 Masayuki Yamanouchi & Makoto Ono, Patents, GETTING THE DEAL 
THROUGH (Mar. 2019), https://gettingthedealthrough.com/area/25/
jurisdiction/36/patents-2017-japan/ [https://perma.cc/ZH67-TFZW]. 
 185 See Tokkyoho Patent Act, supra note 181.  The first subsection states: “An 
employer, a legal entity or a state or local public entity [the “employer”] . . .  shall 
have a non-exclusive license on the patent right concerned.”  See also Naohisa 
Akashi & Manabu Hirata, Revisions Made to the Japan Patent Law Relating to 
Employee Invention System, SEIWA IP NEWS 6 (May 20, 2016), 
http://www.seiwapat.jp/en/IP/pdf/en00029_Employee%27s_Inventions_Refor
m.pdf [https://perma.cc/PWH9-RTB5] (comparing the old and new laws side by 
side). 
 186 See Akashi & Hirata, supra note 185, at 6 (emphasis added). 
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of the patent.187  In this way, Japanese patent law is similar to the 
U.S. common law equivalent of the automatic assignment of an 
expectant interest without requiring a strict parsing of language.  
The shall language, which is used in the statute, is not sufficient to 
pass legal titles under U.S. law, but it is under Japanese law.  In 
summary, this third subsection is clear that “[f]or an invention 
created by an employee, the right to obtain a patent may be assigned 
to an employer or even originally acquired in accordance with rules 
established by the employer, and the said employer may file the 
patent application as the applicant.”188   
The fourth subsection is an employee invention remuneration 
statute.  It was amended in 2004, and then again in 2015.  It explains 
that the employee “shall have the right to a reasonable money or 
other reasonable economical profits . . . when he has enabled the 
right to obtain a patent for an employee invention to belong to the 
employer, etc.” 189   The final subsection elaborates on what is 
reasonable, by explaining that compensation “shall not be 
considered to be unreasonable” where there has been a negotiation 
between the parties, the employer and employee, that was carried 
out with some of established policy or criteria.  This is largely the 
same as the former statute, and affirms case law that “emphasizes 
the importance of adopting reasonable procedures to determine the 
amount of remuneration awarded.”190  With the latest amendment, 
and similar to that seen in relation to reasonable compensation 
under the German employee inventions statute, ArbEG, there are 
guidelines provided to help this determination.191   
 
 187 See id. (“In the case of an invention made by an employee, etc., which 
corresponds to an employee invention, when there is a contractual provision . . . in 
advance that the right to obtain a patent for such an invention shall belong to the 
employer, etc., the right to obtain a patent for such an invention shall inherently be 
vested in the employer, etc., since the occurrence of the right.”) 
 188 Tokkyoho Patent Act, supra note 181, Art. 35. 
 189  Tokkyoho Patent Act, supra note 181, Art. 35.  Cf. Steven Cherensky, 
Comment, A Penny for Their Thoughts: Employee-Inventors, Preinvention Assignment 
Agreements, Property, and Personhood, 81 CALIF. L. REV.  595, 623 (1993) (“It is worth 
noting that the American system of uncompensated contractual cognitive 
assignment is an exception among highly innovative countries. In the United States, 
private employers have no affirmative duty to compensate employees for profits 
derived from their inventions.”). 
 190 LaFrance, supra note 180, at 92. 
 191  See Hiroshi Morita, The Employee Invention in Japan, EU-JAPAN POLICY 
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Due in part to the remuneration statute, and 
[b]ecause Japanese patent law does not distinguish 
deliberate misrepresentations from inadvertent errors in this 
context [joint inventorship, omitting a joint inventor], even 
an honest mistake as to inventorship, or as to the validity of 
an assignment agreement, could lead to invalidation.  This 
result seems unjust with respect to the excluded inventors or 
assignees who acted without fraudulent intent, since the 
invalidation will extinguish their patent rights.192 
Errors in the chain of title may also have a significant impact on 
the question of reasonable remuneration.193   
Finally, in terms of patent assignments, Japanese patent law 
requires that all assignments changing the ownership of a patent be 
registered in the patent registry of the JPO.  The documents 
necessary for this change in ownership are the original or certified 
copy of the patent assignment itself and a power of attorney.194   
4.2. The Korean Approach 
The Korean Invention Promotion Act explains that the 
ownership of a patent originally vests in the employee-inventor, at 
least absent any contractual agreements or any specific employment 
regulations.195  The employer is entitled to a non-exclusive license 
for the patent right that the employee acquires after completing the 
patent process.  This is premised on the idea that the employer 
should have at least a non-exclusive license due to its contributions 
 
[https://perma.cc/MRZ6-5QYA] (introducing the background of employee 
invention law in Japan and recent revisions). 
 192 LaFrance, supra note 180, at 91. 
 193 See LaFrance, supra note 180, at 91 (arguing that errors in inventorship have 
serious impacts on remuneration under Japan Patent Act Section 35). 
 194 Arpita Bhattacharyya, Inventor Oath or Declaration and Assignments, Full 
Disclosure, IP5 OFFICES (Feb. 2016), 
https://www.finnegan.com/files/Upload/Newsletters/Full_Disclosure/2016/F
ebruary/FullDisclosure_Feb16_3.html [https://perma.cc/AU2A-HCWN]. 
 195  Jihyun Kim et al., IP in Business Transactions: South Korea Overview, 
PRACTICAL LAW COUNTRY, Q&A 4-501-7300 (Dec. 1, 2018), https://content.next.
westlaw.com/Document/I2ef129481ed511e38578f7ccc38dcbee/View/FullText.ht
ml?contextData=(sc.Default)&transitionType=Default&firstPage=true&bhcp=1 
(introducing that the ownership of patent vests in the employees originally under 
question No. 22). 
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that lead to the patentable invention of the employee-inventor in the 
first instance.   
Of course, employers do not just want a non-exclusive license, 
and the Korean Invention Promotion Act recognizes this by 
permitting employers to use the mechanism of a contractual 
agreement to alter the original vesting of ownership in the 
employee.  With an employment agreement, for example, much like 
the United States, Korean employers can require their employees to 
transfer all rights to future patentable inventions prior to their 
creation.196   If the ownership has already vested in the inventor, 
meaning there was no contractual agreement in place, and the 
employee decides to assign her inventor to her employer, or, for 
example, an independent contractor sells her patent rights to a 
company, the patent assignment must then be recorded with the 
KIPO.197   The requirements of registration include: (1) a deed of 
assignment that is executed by the assignor, (2) a Notarized 
Corporate Nationality Certificate, also executed by the assignor, and 
(3) a power of attorney of the assignor and the assignee.198  Unlike in 
the United States where a recordation of a patent assignment is not 
required for it to be effective, Korean patent law requires the above 
three steps before the patent assignment is effective.199   
Finally, in the case that the employee must transfer to her 
employer the right to acquire, she is entitled to receive fair 
compensation.200  Many commentators contend that this right to fair 
or justifiable compensation cannot be waived by a contractual 
agreement. 201   If the employee feels the compensation is not 
reasonable, she can challenge the amount.  If a court indeed decides 
the “compensation is unreasonable, a court can decide the amount 
 
 196 Yoon Suk Shin, Eun-Young Park, & Gon-Uk Huh, Patents, GETTING THE 
DEAL THROUGH (Mar. 2019), https://gettingthedealthrough.com/area/25/
jurisdiction/35/patents-korea/ [https://perma.cc/B7ZF-NG9E]. 
 197 See id. (introducing that the patent assignment shall be recorded before 
KIPO). 
 198 Bhattacharyya, supra note 194, at 2. 
 199 See Bhattacharyya, supra note 194, at 2 (showing the differences in patent 
assignment laws in different countries and regions). 
 200  See Jihyun Kim et al., supra note 195 (explaining that The Invention 
Promotion Act provides a right of fair compensation for employees). 
 201 Mikyung Choe & Yoon Chang Lee, The Challenges of Patent Applications for 
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of the compensation by taking into account the profit earned by the 
employer based on the employee’s invention, along with any other 
circumstances relating to the [intellectual property rights].”202   
4.3. The Chinese Approach 
Chinese patent law divides inventions into two categories: non-
service invention-creation and service invention-creation. 203   For 
non-service invention-creations, the ownership of the invention 
vests in the inventor herself.204  In contrast, for service invention-
creations, what we generally think in the United States as employee 
inventions, the ownership of the invention vests directly to the 
inventor’s employer.205   
Like Germany, Japan, and Korea, Chinese patent law has specific 
laws regarding the compensation of employee inventors.  
Specifically, Chinese patent law and its Implementation Rule state a 
basis for inventor rewards (one-time payments) and remuneration 
(royalty payments), yet other authorities in the country have issued 
their own regulations.206  These various remuneration statutes are at 
conflict with each other, with some practitioners commenting on the 
inconsistency.207   
In terms of actual recordation, and the recognition of 
recordation, of ownership changes, Chinese patent law is somewhat 
unique to the other IP5 countries.  While patent assignments are 
permitted, all assignments to a “foreigner, foreign enterprise, or 
other foreign organizations must be approved by the relevant 
department under the State Council.”208  Moreover, if the right to 
apply for a patent is assigned, as in the case of an employee 
 
 202 Id. 
 203  Jeffrey P. Langer, Proposed Changes to China’s Inventor Reward and 
Remuneration System, OSHA LIANG (July 25, 2017), https://oshaliang.com/
newsletter/proposed-changes-to-chinas-inventor-reward-and-remuneration-
system [https://perma.cc/YE8W-B9P8]. 
 204 Id. ¶ 2. 
 205 Id. ¶ 2. 
 206 Xiunan Jin, Case Study: How to Reward and Remunerate Inventors in China? 
IPWATCHDOG (Oct. 13, 2016), http://www.ipwatchdog.com/2016/10/13/reward-
remunerate-inventors-in-china/id=73533/ [https://perma.cc/A9N8-S555]. 
 207 See, e.g., id. (stating that inconsistency exists regarding the amount of the 
inventor remuneration and industries stakeholders are uncertain how the laws will 
be applied and interpreted). 
 208 Bhattacharyya, supra note 194, at 2. 
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assigning her future rights to apply for a patent, a written 
contractual agreement between the parties must be “registered with 
the patent administration department under the State Council.”209   
5. MOVING TOWARDS TRANSPARENCY & PREDICTABILITY 
As Part 1 identified, proving patent priority is fundamental to 
the successful granting, in the first instance, and, the focus of this 
Article, the defense of a post-grant patent.  As the different 
approaches taken in the IP5 countries demonstrate, there are various 
ways to structure the initial decision of ownership and identification 
of inventor, as well as to transfer or otherwise assign the ownership 
of the patent by statutes or individual contractual agreements.   
What is clear in all of these approaches is that ex ante 
transparency and predictability of patent priority would reduce 
transaction and litigation costs.  It would reduce transaction costs, 
when either practitioners are taking on a new client or assessing an 
infringement action (whether as plaintiff or defendant) for a current 
client, as the practitioner would be able to quickly assess patent 
ownership and the effective global date.  In this way, they would not 
need to do extensive file searching, retroactive assignments, or go 
through patent error correction with their local or foreign patent 
office.  If they do need to take those measures, it will be out of 
certainty of a position, rather than a “just-in-case” position.   
Further, more transparency and higher predictability regarding 
global priority dates prior to post-grant opposition proceedings or 
invalidity litigation would reduce litigation costs, as well as 
certainly, as parties would know quickly whether a priority 
challenge is likely to win or not in a post-grant challenge.  Currently, 
due to the disparate patent assignment laws and procedures, there 
is unpredictability that favors an expensive litigation strategy.  This 
litigation strategy involves simply challenging priority to try and 
obtain information that may disrupt the effectiveness of the at-issue 
patent.  Patent holders that are particularly likely to see this sort of 
priority challenge are those that have gone through mergers, 
acquisitions, or other structural changes, ones that may affect the 
ownership of patents.  Moving towards better transparency and 
predictability of global patent priority is the focus of the two new 
proposals. 
 
 209 Bhattacharyya, supra note 194, at 2. 
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5.1. Utilizing Current Secured Transactions Recordation Systems 
In a 2016 study conducted by AIPPI, the International 
Association for the Protection of Intellectual Property, groups 
representing different countries responded to a questionnaire 
regarding whether the group’s current law permitted the possibility 
of creating security interests over intellectual property rights.210  Out 
of the more than forty countries that responded, just three 
responded in the negative.211   Each group was generous in their 
response regarding their respective country’s adoption of a secured 
transactions law, often explaining how their respective secured 
transaction worked in their country. 
This study and its responses evidences a level of comfort in 
secured transactions law throughout the world.  For all five IP 
Offices, the countries in which they are housed responded that they 
did indeed permit parties to grant security interests in patents.  
Moreover, they responded “yes” to the following question: “Is your 
Group’s current law regarding security interests over IPRs sufficient 
to provide certainty and predictability to the parties?”212  Moreover, 
countries that do not provide “visible records” (searchable 
recordation system), like Germany, still feel that parties practicing 
within Germany have sufficient predictability and certainty 
regarding their secured transactions laws.   
For a bit more detail on secured transactions in practice, consider 
the United States, for example.  In the United States, the drafters of 
 
 210 AIPPI, Summary Report—Security Interests Over Intellectual Property (2016), 
http://aippi.org/library/summary-report-general2016/ 
[https://perma.cc/5U9M-2Q3D].  
 211 Id. 
 212  Id. at 10.  See also AIPPI, Netherlands: Security Interests Over Intellectual 
Property (2016), http://aippi.org/library/security-interests-over-intellectual-
property-40/ [https://perma.cc/2GHS-ZKWY]; AIPPI, Germany: Security Interests 
Over Intellectual Property (2016), http://aippi.org/library/security-interests-over-
intellectual-property-24/ [https://perma.cc/7739-N8LZ]; AIPPI, Republic of Korea: 
Security Interests Over Intellectual Property (2016), http://aippi.org/
library/security-interests-over-intellectual-property-18/ [https://perma.cc/J59V-
ZZM7]; AIPPI, Japan: Security Interests Over Intellectual Property (2016), 
http://aippi.org/library/security-interests-over-intellectual-property-14/ 
[https://perma.cc/32YZ-JZMG]; AIPPI, China: Security Interests Over Intellectual 
Property (2016), http://aippi.org/library/security-interests-over-intellectual-
property-6/ [https://perma.cc/4M8J-7YKV]; AIPPI, United States of America: 
Security Interests Over Intellectual Property (2016), http://aippi.org/
library/security-interests-over-intellectual-property-34/ [https://perma.cc/674H-
WLD3]. 
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the Uniform Commercial Code (“UCC”) developed Article 9, the 
law of secured transactions, from “a motivation to encourage 
lending practices.”213  Most basically, the drafters determined that if 
the law could help reduce a lender’s risk and cost to lend, and 
thereby increase predictability and certainty, then a lender should 
be more willing to enter into transactions with debtors. 214  
Recognizing the need for a uniform system, one that was not 
impacted by individual rules with states, as well as a central place 
for parties to gather information about what financial transactions 
might affect them, the UCC drafters created a uniform, one-page 
UCC financing statement that can be filed online in a matter of 
minutes in each state and province, including D.C. for foreign 
entities, among others.  The UCC recordation system has a pure 
notice function: the financing statement is not detailed, but it must 
contain accurate information on the debtor’s name, the creditor’s 
name, and collateral that is covered.215   
While countries surveyed here have aspects that are unique in 
their secured transactions law, as financing law is typically tailored 
towards the needs and culture of each respective country,216 there is 
also a notable commonality.  Secured transactions laws must be 
predictable, no matter what country they are operating in.  Why? 
The reason is the same everywhere: third parties rely on this 
information when deciding to lend credit to a debtor.  Again, third 
parties do not need access to much detail of any given transaction, 
but they must know who the debtor is, who the creditor is, and what 
the general collateral is.   
In a similar way, patent law needs a central, online recordation 
system for patents.  This would not be necessary for patents that are 
used as collateral to help secure financing, like what the AIPPI 
 
 213  Karen E. Sandrik, Formal but Forgiving: A New Approach to Patent 
Assignments, 66 RUTGERS L. REV. 299, 340 (2014). 
 214 See U.C.C. § 9-101 (1962), official comment (“The aim of this Article is to 
provide a simple and unified structure within the immense variety of present-day 
secured financing transactions can go forward with less cost and with greater 
certainty.”). 
 215 See id. at 7, § 9-502 (introducing the financing statement formal requisites). 
 216 See AIPPI, Japan: Security Interests Over Intellectual Property, supra note 212, 
at 10 & 14, http://aippi.org/library/security-interests-over-intellectual-property-
14/ [https://perma.cc/32YZ-JZMG] (The report from Japan demonstrates this 
uniqueness most visibly, answering “no” to whether it would be desirable to 
harmonize laws governing security interests in IPRs. The reasoning: trying to move 
away from unique national law would create instability and unpredictability in the 
financial markets in Japan and likely around the world). 
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survey was specifically inquiring about, but a central place where 
the ownership of patents can be registered for all to see.  This is 
purely about providing sufficient notice of what the global effective 
date is for any patent, as well as the ownership of the patent.  This 
information should show the chain-of-title, much like what local 
county property offices do for real property here in the United 
States. 
Unfortunately, as the systems are currently set up, again, using 
the United States as a specific example, the systems are designed 
specifically to gather information regarding a debtor, creditor, and 
collateral.  The secured transactions systems are not designed to ask 
information about a patent applicant or a patent owner, let alone the 
effective global date of a patent itself.  Certainly, it would not be a 
difficult task, at least compared to most law reform, to enable the 
online systems to intake this information, but it would mean some 
technical overhauling of the online systems and patent laws in each 
country. 
Yet, even if this does not ever happen, looking to the consistent 
and predicable secured transactions laws across the world that 
almost all use some sort of quick, online recordation systems, can at 
least lead to the adoption of similar one-page per patent filing 
systems for tracking the chain-of-title of patent ownership. 
5.2. Requiring Ex Ante Disclosures 
The above section argued that secured transactions law, with its 
notice function of recordation, should provide an example, if not in-
place model, for creating more predictability and certainty for 
patent priority in a global market.  This subpart suggests that either 
coordinating with a centralized recordation system, one that would 
be online for anyone to search, or building new disclosure 
requirements into an already-existing system, would create a 
common notice system in regard to the priority date of patents.   
A centralized recordation should likely be housed at the World 
Intellectual Property Organization (“WIPO”), which is also the place 
where PCT applications are filed as a part of fulfilling its mission.  
The WIPO is also ideal space, as its mission is to “promote[] 
innovation and creativity for the economic, social and cultural 
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development of all countries, through a balanced and effective 
international intellectual property system.”217   
As stated above, the PCT, the Patent Cooperation Treaty, 
sometimes also referred to as the “international patent system,” 
helps patent applicants seek patent protection in countries outside 
of their local country.218  Patent applicants can file an international 
patent application, which will then jumpstart a process to selecting 
one or more of the 153 PCT Contracting States, from the United Arab 
Emirates to Zimbabwe, and many in between.219   
When filing the international patent application under the PCT, 
the patent applicant has the opportunity to use the priority date of a 
national, or local patent.  For example, if a patent is first filed in 
China, the patent owner then has up to twelve months to file the 
patent application, link it, and use the priority date of the Chinese 
patent.  Accordingly, adding very specific questions that would 
auto-fill into a centralized database would be relatively easy.  
Simply, where is the country of origin?  What is the claimed effective 
priority date?  Who is the patent owner of the Chinese patent?  Who 
is the PCT applicant?  Ideally, of course, the last two questions will 
have the same answer.  If the answers are not the same, it will at least 
trigger an automatic inquiry by WIPO and the patent applicant 
herself.  This automatic function would also function to help bring 
notice to the potential chain-of-title immediately, as opposed to 
having memories and records stale for years before the issue is ever 
noticed.  
This same type of centralized recordation system, if not housed 
by WIPO, could also be a simple add-on to the unitary patent 
system.  The EPO has stated that the unitary patent system is 
scheduled to launch by the end of 2020.220  Given that many of the 
priority challenges are occurring in EU oppositions, this simple yet 
 
 217 See Homepage, WORLD INTELL. PROP. ORG., https://www.wipo.int/portal/
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effective centralized recordation system is particularly relevant to 
the newly proposed unitary patent system.  Again, the additions 
would be easy: just a couple more questions to answer when filing 
with the EPO.  
Overall, filling out basic chain-of-title information at the same 
time as the filling of the PCT application or EPO unitary patent 
application would help prevent simple mistakes from happening, or 
lapsing in memories or written records.  While each country will 
continue to have their own unique approach to initial patent 
entitlement, mechanisms for patent assignments, and decisions 
whether to provide additional monetary payments to employees, 
each country can use a common system of notice.  This system of 
notice is one that is already used across the world in secured 
transactions laws to increase transparency and predictability, and, 
thereby, certainty, to all parties within the global patenting 
marketplace. 
CONCLUSION 
Employee inventions are an important source of innovation 
around the world, yet the assignment of these inventions are also a 
source of transactional inefficiency and increased patent litigation.   
By itself, conveying legal title of a patent is not difficult, yet it 
becomes more complex when the rules of patent assignments 
regarding patent priority are different from country to country.  
There is no worldwide, uniform approach for parties to follow when 
assigning patents in order to avoid future patent priority challenges.  
This creates opportunity for parties to capitalize on drafting errors, 
omissions in a complex merger or acquisition, or simply 
disorganized corporation record-keeping systems.   
More so than ever before, innovation requires a multinational 
approach, one where global partners have accurate information 
about one another, both to help assess the competition and to decide 
when a partnership is worth building.  This Article has argued that 
creating a centralized recordation system, one based upon already-
existing secured transactions databases, would help reduce the 
amount of opportunism and user errors by promoting transparency 
and predictability, while also providing an easy way to ensure that 
information regarding priority and chain of title is valued and 
encouraged.  Though no worldwide centralized system currently 
exists, there are groups, such as the AIPPI and IP5, that have 
Published by Penn Law: Legal Scholarship Repository,
808 U. Pa. J. Int'l L. [Vol. 41:3 
expressed an interest in the connection of secured transactions law 
and intellectual property law.  And, finally, even if no centralized 
databased is built, there are also opportunities to build disclosures 
into already-existing multi-country patenting processes in Europe.  
This is particularly true with the unitary patent system that is 
scheduled to launch in Europe at the end of this year. 
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